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the NHMrc clinical trials centre at the university of sydney conducts 
investigator-initiated clinical trials with national and international 
collaborators, and contributes expertise to trials run by others. it also:
•	 takes a lead in proposing new directions for clinical research in Australia, 
particularly research aligned with national policy and clinical practice
•	 participates in translational research, from bench to bedside
•	 conducts methodological research in relation to clinical trials
•	 reviews and synthesises evidence from completed trials,  
and is at the forefront of developments in methods,  
such as prospective meta-analysis
•	 supervises postgraduate students in all of these areas
•	 offers postgraduate degrees in clinical trials research
•	 runs short courses in all aspects of clinical trials to train people for 
Australian medical research.
•	 undertakes health technology and diagnostic test assessments, economic 
analyses, biostatistical design and analysis, and automated central 
randomisation services.
core funding is provided by the NHMrc, and specific projects  
are funded by government, public and private institutions  
and the pharmaceutical industry. 
the ctc is at two sites in camperdown in inner sydney —  
the Medical foundation building on parramatta road and  
chris o’brien Lifehouse on Missenden road.
this report describes highlights of the ctc’s achievements for 2016. 
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DIreCTOrS’ repOrT 
2016 was another year of continuing 
strong research achievement. our aim 
has been to lead high-quality clinical 
research, develop new trial methods, 
and to integrate trial evidence in 
new analysis. we initiated, led or 
collaborated in a growing number of 
studies started or completed, and had 
the satisfaction of seeing reports of 
completed research at a new high. 
this report highlights examples 
from the past year of trials in our 
established clinical areas: oncology, 
cardiovascular disease, diabetes 
and perinatal medicine, which 
together account for a substantial 
part of Australia’s disease burden. 
our trials program has covered 
the full spectrum of clinical trials 
research, from small trials aimed 
at evaluating targeted therapies 
for individual patients through to 
large-scale trials in areas where 
moderate treatment effects lead to 
substantial public health benefit. our 
work in methodology, translational 
studies, and integrational studies, 
such as meta-analysis and economic 
evaluation, provide a firm footing and 
context to our trials.
we have a strong commitment to 
keep training the next generation of 
biomedical researchers. As well as 
personal supervision of phD and other 
research students, ctc’s academics 
all play a part in postgraduate 
courses, masterclasses and workshops 
designed to improve the quality 
of scientific and clinical research in 
Australia.
this report includes some inspiring 
stories of past postgraduate 
students who have been trained and 
postdoctoral trainees who have been 
mentored at ctc. they have gone 
on into the wider world to rewarding 
and fruitful careers shaped by the 
experience. they have carried the 
experience and knowledge gained 
at ctc into various academic, 
government and health care settings. 
Most continue to work with ctc 
as valued collaborators. there are 
also some personal stories of ctc 
collaborators and current ctc staff 
who are undertaking excellent work 
in clinical trials research.
our contributions to national 
and international investigator-
initiated clinical trials and associated 
research in oncology have led to 
improvements in quality of life, 
survival and cancer control, and to 
new research questions. some of 
the trials leading to new findings 
and completed in 2016 (in breast, 
gastrointestinal, gynaecological, 
lung, brain and urogenital cancers), 
conducted as collaborations with 
national investigator groups, are 
highlighted in this report.
these examples also reflect the shift 
in cancer treatment research toward 
immunotherapy and personalized 
medicine: many of the trials, such as 
tActic and icecreAM, now select 
patients on the basis of individual 
genetic characteristics and most 
include analysis of tumour tissue 
and blood for indicators for future 
research. we also highlight some 
studies in which meta-analysis of 
biological data linked with clinical 
outcomes from several trials has 
led to definitive evidence to inform 
clinical guidance.
in cardiovascular disease, we were 
pleased to report the extended 
follow-up over 16 years of the 
LipiD study, which showed that 
patients treated with pravastatin had 
sustained survival benefits with no 
adverse effects on non-cardiovascular 
deaths or cancer. the evidence that 
cholesterol lowering with statin 
drugs prevents cardiovascular events 
and deaths continues to grow even 
for those at low risk of such events 
and for a wide range of groups—
including women—based on the 
the international meta-analyses 
prospectively planned by ctc jointly 
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with the clinical trials service unit 
in oxford. 
ctc’s other historic large 
cardiovascular trial, fieLD, which 
enrolled nearly 10,000 patients 
with type 2 diabetes, has been a 
springboard for investigations of new 
indications for fenofibrate, including 
fAMe1-eye, which is investigating 
retinopathy in type 1 diabetes. our 
diabetes research extends to type 
1 diabetes trials in remote areas, 
new indications for a simple drug 
(metformin), improving availability 
of insulin treatment internationally, 
use of advanced insulin pump and 
glucose sensors in type 1 diabetes, 
and, especially, the search for better 
ways of producing insulin when the 
pancreas fails. our diabetes group has 
a strong commitment to teaching, 
including each year offering summer 
scholarships to medical students 
and training graduates in the 
fundamentals of biomarkers.
we are currently conducting six large 
international trials in perinatal or 
neonatal medicine. in neonatal trials, 
in common with many prevention 
trials, treatment benefits may be 
moderate, so they may require 
thousands of patients to arrive at 
reliable results. they require special 
efforts to make them simpler, more 
inexpensive and efficient, and 
reflect the urgency of making trials 
a routine part of clinical practice. 
ctc’s neonatal group is focusing 
on staff development, point-of 
care data collection, close liaison 
and partnership with parents, and 
clarifying benefits and harms for 
parents. in 2016, we reported the 
results of the boost ii neonatal 
oxygen trials, whose data are now 
contributing to the international 
NeoproM meta-analysis we are 
leading.
in 2016, ctc’s methodological 
experts made substantial 
contributions to our own trials and 
many other international trials, and 
a wide variety of clinical areas in 
Australia. biostatistics is the core of 
most clinical research projects, and 
our biostatisticians are committed to 
sharing their expertise in consulting, 
postgraduate courses and regular 
workshops, as well as training 
biostatisticians for Australian research 
in the biostatistics collaboration of 
Australia.
A long-standing aim of ctc is to 
help bridge the gap between research 
evidence and clinical practice through 
integration of trial results with other 
evidence and through economic 
analyses. in 2017, the cochrane breast 
cancer Group, whose editorial base is 
at ctc, reached 20 years of facilitating 
and coordinating reviews and updates 
of breast cancer evidence for the 
world. we also completed a major 
review of the evidence on the value of 
fluoride in water supplies in Australia 
and reviews of new technology for 
government.
in Australia, rapid growth in health 
technologies contributes to the 
continuously increasing rise in health 
care costs, now over $150 billion a 
year. in this environment, new and 
existing recommendations and policy 
will be based on sound evidence of 
cost-effectiveness and strategies 
that are smarter and better targeted. 
trial programs have been shown 
by us and others to be much more 
cost-effective use of the health care 
dollar than many of the treatments 
accepted into routine care.
None of our achievements could 
happen without the efforts of many 
people. we are fortunate to work 
with exceptional individuals in our 
collaborating investigator groups 
and other research organisations 
in Australia and internationally. we 
appreciate the efforts of ctc staff; 
the quality and extent of their work 
is reflected in the achievements 
reported here.
CTC executive:  
John Simes, 
director;  
Vera Terry, 
business 
director;  
Wendy Hague, 
clinical trials 
program 
director;  
and Anthony 
Keech, deputy 
director
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JOhn SIMeS’ 
leaDerShIp 
reCOgnISeD
John simes received three major 
awards in 2016, which reflect the 
many achievements of the clinical 
trials centre and its collaborators 
over nearly 30 years. 
the Nsw premier’s outstanding 
cancer researcher of the year award 
was for leadership in clinical trials 
and translational research. the 
Alan coates Award for excellence in 
clinical trials research recognised 
a research career over four decades, 
including contributions to the 
Australian and New Zealand breast 
cancer trials Group. And colleagues 
in cancer research honoured 
him with the cancer research 
Network’s 10th Anniversary career 
Achievement Award for broad areas 
of leadership, advocacy, research, 
and teaching.
John simes has helped establish 
or develop national cancer research 
groups, which run high-quality 
clinical trials in areas of need, often 
in collaboration with ctc. He is a 
founding director of the Australian 
clinical trials Alliance (the peak 
body for advancing trials research 
in Australia’s health system) and of 
the Australian New Zealand clinical 
trials registry, and founding director 
of sydney catalyst.
John simes has been a tireless 
champion of the value of clinical 
trials and was an early advocate of 
making trials research a routine part 
of clinical practice. the monetary 
value of these awards will be used 
to help provide endowments for 
postgraduate research students.
Top: Outstanding Cancer Researcher of the Year, with Morris Iemma,  
Cancer Institute chair
Middle: John Simes, Alan Coates (right), a founder of the Australian and 
New Zealand Breast Cancer Trials Group (ANZBCTG), and Stephen Ackland, 
ANZBCTG chair (left)
Above: Graham Mann of the Cancer Research Network with John Simes
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OnCOlOgy TrIalS
the ctc has long-standing relationships with national cancer cooperative 
groups and is well represented in clinical trials initiatives in cancer. it has 
collaborated in over 170 cancer trials recruiting many thousands of patients in 
breast, oesophageal, gastric, colorectal, lung, gynaecological, neurological, and 
urogenital cancers and melanoma.
the ctc is the coordinating centre for the:
•	 Australasian Gastro-intestinal trials Group (AGitG)
•	 Australasian Lung cancer trials Group (ALtG)
•	 Australian and New Zealand urogenital and prostate cancer trials Group 
(ANZup)
•	 Australia New Zealand Gynaecological oncology Group (ANZGoG)
•	 cooperative trials Group for Neuro-oncology (coGNo).
•	 and statistical centre for the Australia and New Zealand breast cancer trials 
Group (ANZbctG).
in the conduct of trials, the ctc covers the full range of responsibilities — from 
assisting in establishing new groups by creating a research governance structure 
and terms of reference, identifying important questions related to public health 
— through to large-scale trial operations in collaboration with the groups, for 
example, in concept and protocol development, randomisation, data collection, 
ethics and regulatory compliance, on-site monitoring and audit, and analyses 
and manuscript preparation.
anZ bCTg
the Australian and New 
Zealand breast cancer trials 
Group conducts a program 
of multicentre national and 
international clinical trials 
involving over 700 researchers. 
its trials cover all aspects of 
breast cancer, including new 
treatments, prevention, quality 
of life, and treatment cost-
effectiveness.
ctc is biostatistical centre 
for trials coordinated by the 
ANZ bctG, and has a formal 
relationship with the group 
spanning nearly 30 years.
Burcu Vachan, oncology program 
manager, operations
Felicia Roncolato and Nicola Lawrence, clinical research fellows 
for ANZUP urogenital trials, with colleague Deme Karikios
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Completion of 
InTegraTe trial leads to  
InTegraTe II
the AGitG-ctc iNteGrAte trial 
was completed and its results 
published in the Journal of Clinical 
Oncology in 2016.141 it was one of 
the journal’s most accessed and 
important articles for the year 
and was promoted to oncologists 
worldwide in a special journal 
collection.
the iNteGrAte trial was the first 
study to show that regorafenib 
(a treatment that inhibits the 
growth of abnormal cells and 
blood vessels) was active against 
oesophagogastric cancer after 
chemotherapy had failed to arrest 
the disease.
As a phase 2 trial, iNteGrAte 
was designed to show the 
response the tumour to 
regorafenib and that it was safe, 
but it also had a placebo arm as 
a calibration group. there was a 
significantly lower rate of disease 
progression or death among 
patients receiving regorafenib, 
18%, compared with placebo, 
46%. this was more marked 
in the south Korean patients, 
possibly because of genetic 
differences or differences in the 
way the drug is metabolised in 
different populations. this finding 
raises important questions for 
future research. the first of several 
planned molecular biomarker 
studies was presented at an 
international meeting in January 
2016. the study found several 
strong molecular correlations 
with responses to treatment 
and inter-country differences, 
Katrin Sjoquist, CTC’s clinical lead for trials in gastrointestinal  
and gynaecological cancers
agITg
the Australasian Gastro-intestinal trials Group has been conducting trials 
in gastrointestinal cancer with ctc since the early 1990s.
the group’s purpose is to achieve better health outcomes for patients 
with gastrointestinal cancers by conducting and promoting clinical and 
related biological research in Australasia and internationally.
the AGitG is strongly focused on encouraging members of the medical 
and scientific community to participate in AGitG-sponsored trials. 
Members are actively engaged in identifying and developing novel clinical 
questions to answer in trials addressing common or rare gastrointestinal 
cancers. several of these trials have led to improvements in clinical 
management internationally.
Cheryl Friend, associate oncology program manager, AGITG trials
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but so far no clear basis for predicting 
prognosis or the likely effect of 
treatment in individuals.
on the basis of the success of 
iNteGrAte, the investigators have 
started a phase 3 trial, iNteGrAte ii, 
to investigate whether regorafenib 
prolongs survival in patients overall 
and in an Asian subpopulation. 
biological samples from patients will 
again be used to identify biomarkers 
that predict study endpoints relating 
to survival, response, and safety 
and to further investigate the 
questions about biology and regional 
differences. the study will recruit 
patients from Australia, New Zealand, 
Korea, Japan, taiwan, canada and the 
united states over the next 2 years. 
patients with bile duct 
cancers selected for 
treatment by gene testing
the AGitG-ctc biliary tract cancer 
trial, tActic, was completed and 
published in 2016. the results 
showed that a monoclonal 
antibody, panitumumab, is likely 
to be a suitable targeted treatment 
for selected patients with biliary 
tract (bile duct) cancers.53 tActic 
also showed that the new drug 
can be combined safely with 
standard cisplatin and gemcitabine 
chemotherapy.
tActic was a phase 2 trial 
investigating the feasibility of 
selecting patients for treatment with 
panitumumab on the basis of gene 
testing. this approach had been 
successful in trials of other cancer 
types. this experience, supported 
by evidence that some biliary tract 
cancers responded to panitumumab, 
provided the rationale for tActic. 
patients with advanced or inoperable 
tumours were eligible for the trial 
if tumour testing before enrolment 
showed no mutations in the 
KRAS gene.
biliary tract cancers are rare, which 
can be a challenge for trials research. 
tActic surpassed its target and 
recruited 45 eligible patients. of 
these, 80% had a clinical benefit 
from the treatment when tested after 
3 months, an improvement over the 
rate with chemotherapy alone.
the investigators consider that this 
rate of benefit might be even better 
with finer selection of patients. 
tumour genes can be tested further 
for other mutations that might 
predict how well this antibody 
treatment works for an individual. 
this is a promising area for further 
research to improve the prospects of 
patients with biliary tract cancers.
ICeCreaM colorectal cancer 
trial answers questions and 
opens up new hypotheses
bowel cancer is relatively common, 
and accounts for about 10% of all 
cancers. when it has metastasised, 
it is not curable, but new treatment 
regimens have been improving 
survival, so that now many patients 
survive for years.
in particular, molecular biomarkers 
can indicate whether specific 
biological treatments are likely to be 
successful. patients are increasingly 
being offered treatments tailored to 
their individual cancers. patients with 
bowel cancers with specific genetic 
mutations are known not to benefit 
from some antibody treatments. 
However, before the icecreAM 
trial, a question remained about 
one mutation variant. some small 
retrospective studies had suggested 
an antibody treatment, cetuximab, 
might be effective for tumours with 
the relatively rare G13D mutation. 
icecreAM addressed this question 
eric Tsobanis, manager of the INTeGRATe trials

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and also aimed to evaluate whether adding standard 
chemotherapy would improve outcomes.
the cetuximab treatment alone was not effective, 
although some patients who received chemotherapy 
as well appeared to benefit, an unexpected result. 
icecreAM can claim several achievements. it showed 
that tumours with the G13D mutation did not respond 
to cetuximab treatment. its results suggested that 
there could be a synergistic effect of cetuximab with 
chemotherapy, or that repeat chemotherapy could be 
effective after an interval without treatment.159 these 
are new questions for further research. icecreAM also 
reinforced the value of a prospective trial to test findings 
from retrospective analyses and demonstrated that 
treatments for rare molecular subtypes of cancer could 
be evaluated in clinical trials. 
icecreAM is continuing with a larger patient group, 
with the aim of answering the second question: does 
cetuximab make chemotherapy more effective? only 
patients with non-mutated tumours are being selected 
for part 2.
Subotheni Thavaneswaran, clinical research fellow for 
ICeCReAM and other gastrointestinal cancer trials
anZgOg
the Australia New Zealand Gynaecological 
oncology Group conducts research into 
cancers of the ovaries, cervix, uterus, vulva 
and vagina at sites throughout Australia 
and New Zealand. ANZGoG collaborates 
with over 20 study groups in other countries 
through membership of the international 
Gynecologic cancer intergroup. current 
trials of the ANZGoG-ctc collaboration are 
investigating chemotherapy, immunotherapy, 
hormone blockers and exercise for a range of 
gynaecological cancers.
ANZGoG has members in all medical and 
health specialties, as well as patients and 
other non-professional members, some of 
whom form an advisory panel for consumer 
outreach and trial development.
Peey Sei Kok, clinical 
research fellow, ALTG 
and ANZGOG trials

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GYNAeCOLOGICAL CANCeR: HIGHLIGHT
Measuring the effects of 
treatment from patients’ 
reports
quality of life and other patient-
reported outcomes are important 
criteria for evaluating treatments 
for ovarian cancer—at least as 
important as objective measures 
such as the response of a tumour 
to treatment or survival time. 
Most women with ovarian cancer 
have advanced-stage disease and 
their priority is not survival but to 
maintain their quality of life and 
to reduce distressing symptoms.
Due to concern that this issue 
may be neglected in clinical 
trials, a recent systematic review 
of phase 3 trials evaluated the 
content of trial protocols in 
relation to patient reported 
outcomes.120 Although most 
of the trials reviewed used a 
patient-reported primary or 
secondary endpoint, less a third 
had an explicit patient-reported 
objective. the researchers 
concluded that clear guidance is 
needed for ensuring that patient-
reported outcomes are properly 
included in protocols for new 
ovarian cancer trials.
including patient-reported 
outcomes in trials also 
acknowledges that patients make 
a major contribution to research, 
often without expectation of 
personal benefit, when they 
consent to participate. policies of 
ctc and its collaborators aim to 
ensure that patients are involved 
and informed at each stage of 
all trials.
Personal story
JOhn STark:  
COOrDInaTIng TrIalS MakIng  
a DIfferenCe In gynaeCOlOgICal CanCer
one of the most motivating aspects of working as a trial coordinator 
at the ctc is having a hand in multiple studies. operating across 
different patient populations—in terms of disease of origin and disease 
staging—has allowed me to broaden my knowledge set and ensure 
that no two days are ever the same. 
2016 gave me an opportunity to coordinate three ANZGoG studies, 
all of which were at different stages of their life cycle. pArAGoN was 
an open phase 2 trial of an oral hormone treatment for women with 
gynaecological cancers, with patients in europe and Australia. it closed 
to recruitment and there was extensive data cleaning to ensure we were 
prepared for subsequent statistical analysis and manuscript writing. 
ecHo is evaluating the effect of 18 weeks of aerobic and resistance 
exercise during chemotherapy and for up to 18 weeks for women with 
ovarian cancer. the trial has been recruiting steadily and achieved the 
milestone of 50% of its overall target. the pHAeDrA trial has been 
preparing to open to recruitment. pHAeDrA is investigating the 
effect of a targeted antibody treatment in two groups of women with 
different gene types. setting firm groundwork in 2016 will ultimately 
ensure that 2017 is a productive and conducive year for these studies. 
it is rewarding to be aware that my work will play a part in improving 
the lives of women with gynaecological cancers. 
John Stark, trial coordinator for ANZGOG, with colleague Anna Walsh
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Should glioma patients 
have chemotherapy,  
and when?
High-grade glioma is a relatively 
rare aggressive brain tumour that 
most commonly affects people 
in middle adulthood. it is treated 
by surgery to remove the tumour 
as far as possible, followed by 
radiotherapy with or without 
chemotherapy. 
A potentially practice-changing 
trial, cAtNoN, which may improve 
the survival of people with these 
tumours has started showing 
promising results. cAtNoN is an 
international phase 3 trial led by 
the european organisation for 
research and treatment in cancer 
and is a coGNo-ctc collaboration 
in Australia. the trial is taking 
advantage of modern methods 
of genetic selection to advance 
targeted individual treatment.
it has been known that 
temozolomide chemotherapy 
can delay the growth or spread of 
a high-grade glioma in patients 
who have a specific genetic flag: 
that is, in their tumour cells the 
1p and 19q chromosome arms 
are missing. for others, who do 
not have this genetic type, it has 
so far not been clear whether 
chemotherapy performs similarly. 
to answer this question, cAtNoN 
has enrolled 748 patients 
worldwide without the deletion 
of 1p and 19q, with 82 patients 
coming from the sites from within 
the coGNo group. they have 
been allocated to one of four 
treatment regimens: 33 daily 
doses of radiation alone; the same 
radiation with concurrent daily 
oral temozolomide chemotherapy; 
12 weeks of chemotherapy after 
the end of the radiotherapy; or all 
these treatments.
the patients are still being 
followed up, but promising and 
important interim results were 
presented at a plenary session of 
the 2016 meeting of the American 
society of clinical oncology. the 
patients in the two groups who 
received chemotherapy after 
radiotherapy had twice as long 
before their tumour began to grow 
again. At 5 years, 56% were alive, 
compared with 44% of those in 
the other two groups. 
the investigators are also 
conducting detailed genetic 
studies of tumour samples to 
further identify the characteristics 
of individual patients who are 
most likely to benefit from 
temozolomide chemotherapy.
Merryn Hall, associate oncology program manager, operations, for the Cooperative Trials Group 
for Neuro-Oncology, who oversees project management of the CATNON trial
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COgnO
collaborative research by ctc 
and the cooperative trials 
Group for Neuro-oncology 
has the purpose of better 
outcomes for those with brain 
tumours, and others affected 
by these diseases, such as their 
families. coGNo’s main aim 
is to conduct investigator-
initiated and collaborative 
group trials addressing 
important clinical questions 
that matter to patients. 
coGNo now has members 
in New Zealand, singapore, 
canada, ireland, india, sweden 
and the usA. the group also 
has consumer and industry 
associate members. coGNo’s 
annual scientific meetings 
have been hugely successful in 
bringing together professionals 
from all over the world.
Jenny Chow, executive officer for the 
Cooperative Trials Group for Neuro-
Oncology (COGNO)
CtC alum
anna nOwak:  
leaDIng reSearCh TranSlaTIOn 
TO fIghT DeaDly CanCerS
What do you do now?
i’m professor in medical oncology at the 
university of western Australia and a 
medical oncologist at sir charles Gairdner 
Hospital in perth. i mainly treat patients 
with mesothelioma—the lung cancer caused 
by asbestos exposure—and glioblastoma 
brain tumours. caring for patients with these cancers is immensely 
rewarding. this motivates my research, aimed at improving the 
treatment and prospects of patients with these diseases, where there 
are few options. As a clinician and researcher, i am able to make a 
difference to national and international research progress and to teach 
and mentor young oncologists.
in Australia, and especially western Australia, the rate of mesothelioma 
is high by world standards, because of our extensive mining and use 
of asbestos. because of the lag between exposure and illness, the rates 
have not gone down and may be increasing. it is a deadly disease, 
like many lung cancers, and is desperately in need of new treatments. 
My phD was a study of combined chemotherapy and immunotherapy 
for mesothelioma in mice. immunotherapy has progressed remarkably 
since then and become mainstream, although mesothelioma is a 
difficult area. we are trying to translate successful treatment regimens 
in mice to treatment that works for patients.
When were you at CTC?
in 2003–2004 i was the inaugural postdoctoral fellow in clinical trials 
and quality of life at ctc, working with Martin stockler and John simes. 
it complemented my phD experimental research, revealing the full 
translational research pathway. 
How did your CTC experience influence your career?
while i was at the ctc i was able to make invaluable contacts with 
people who are still at the centre of academic trials research in 
Australia and to understand how the cooperative trials groups worked. 
i collaborate with the ctc still, through ALtG and coGNo. currently, 
i’m principal investigator on DreAM, which is using combined 
chemotherapy and durvalumab, an immune checkpoint inhibitor, 
for mesothelioma. As well as looking at the effect of treatment, we 
are collecting biological samples for analysing individual predictors 
of treatment benefit. DreAM has really drawn together my phD and 
subsequent laboratory work with the skills i gained at ctc. i am also 
leading the Australian part of cAtNoN and contributing to other brain 
and lung cancer trials.
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CtC alum
peTer grIMISOn,  
SyDney CanCer ClInICIan  
anD leaDer Of ClInICal 
TrIalS
What do you do now? 
i am a medical oncologist at the chris 
o’brien Lifehouse cancer hospital in 
sydney and see patients with testicular 
cancer, other genitourinary cancers, and 
upper gastrointestinal cancers. An important aspect of my work 
is coordinating and teaching in the royal Australasian college of 
physicians program for advanced trainees in medical oncology. 
i also teach students in the university of sydney Medical program, 
and serve on the Australian Government pharmaceutical benefits 
Advisory committee.
the Australian cancer cooperative groups of investigators initiate 
and conduct trials where clinicians and patients have identified a 
need for them. i am involved as a leader and study investigator 
in trials for two of these groups: the Australian and New Zealand 
urogenital and prostate group and the Australasian Gastro-
intestinal trials Group. i chair ANZup’s phase 3 Accelerated bep 
trial, which is following a successful phase 2 trial, and currently 
recruiting. it has attracted strong international interest, with 
participation from groups in the uK and usA.
Nausea and vomiting in patients undergoing chemotherapy is a 
major problem affecting quality of life. in 2016, a group that i am 
chairing began the largest and most definitive randomised trial of 
medical cannabinoids to prevent chemotherapy-induced nausea, 
cannabis ciNv, which is being coordinated at ctc. 
When were you at CTC?
in 2009, as a newly certified medical oncologist, i completed a phD 
in quality-of-life assessment in clinical trials, and developed a utility 
measure that has informed analyses of quality of life and quality-
adjusted survival in recent trials.
How did your CTC experience influence your career? 
ctc is a fertile training ground for all aspects of clinical trials, with 
incredible opportunities for mentoring by Australia’s leading clinical 
researchers. this has enabled me to lead and contribute to trials 
in my areas of interest. i learned research methodology, including 
concept and protocol design, how to incorporate patient-reported 
outcomes and health economic evaluations, trial operations, and 
the skills for writing conference abstracts, manuscripts and grant 
applications. 
UROGeNITAL CANCeR: HIGHLIGHT
promising efficacy of 
testicular cancer regimen 
Germ-cell tumours, such as testicular 
cancer, typically affect adolescent 
and young adult males. over 80% 
are considered cured after three or 
four cycles of chemotherapy, given at 
3-weekly intervals. this has been the 
standard treatment for a long time, 
but a third of patients with worst risk 
features still relapse and die.
the ANZup-ctc phase 2 
trial, Accelerated bep, showed 
that administering the same 
chemotherapy every 2 weeks instead 
of every 3 weeks was a safe, feasible 
and active treatment. in 2016, the 
investigators published the results 
BReAST CANCeR: SNAC
Sentinel node biopsy 
compared with axillary 
clearance: 5-year outcomes
the sNAc (sentinel Node biopsy 
versus Axillary clearance) trial 
was the first multicentre trial of 
surgical treatment of breast cancer 
in Australasia—a collaboration of 
the ctc and the royal Australasian 
college of surgeons.
thorough biopsy, or full clearance, 
of the axillary lymph nodes can lead 
to arm swelling, pain, numbness 
and restricted movement. in 
sNAc, with the notion that these 
side-effects might be avoidable 
with a less invasive procedure, 
women with single tumours smaller 
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anZup 
the Australian and New 
Zealand urogenital and 
prostate cancer trials Group 
conducts trial research to 
improve treatment of bladder, 
kidney, testicular and prostate 
cancer. it brings together the 
professional disciplines and 
groups researching and treating 
prostate and other urogenital 
cancers and also seeks 
guidance from its consumer 
advisory panel, representing 
those with personal experience 
of these cancers.
ANZup collaborates with 
ctc to conduct independent, 
investigator-initiated clinical 
trials.
of the analysis of survival five years 
after treatment.94 the 5-year survival 
rate was over 90%for all risk groups.
the results of this trial, and other 
evidence, supported the case for 
a phase 3 trial. the ANZup-ctc 
phase 3 randomised trial, p3bep, 
is comparing the new accelerated 
regimen with the standard 3-weekly 
regimen in 500 men, women and 
children with intermediate or poor 
risk germ-cell tumours in Australia, 
New Zealand, the uK and the usA. 
this trial will eventually compare the 
two treatment groups for survival. 
the investigators will compare the 
two treatment arms for changes 
in the size of tumours, changes 
than 3 cm were randomised to 
either full clearance or biopsy of 
sentinel nodes only.
it was found that clinical 
management based on sentinel-
lymph-node biopsy was as accurate 
for diagnosis. both treatment groups 
had moderate limitations in arm 
movement over the first 6 months, 
which then recovered to near normal 
levels. swelling and symptoms 
increased over 2 years and then 
levelled off. 
Data from patients in sNAc were 
assessed after 5 years, though 
objective measurements of arm 
volume and also subjectively by 
questionnaire. the subjective scores 
only moderately correlated with a 
change in arm volume. the 5-year 
results showed that the women who 
had only the sentinel-node procedure 
on average still had less swelling and 
reported better quality of life on the 
questionnaires. the 5-year results 
were published in 2016.198 ten-year 
follow-up is now complete, and 
analyses are assessing the relative 
survival of the randomised groups.
the sNAc 2 trial is currently in 
progress. the investigators are 
recruiting women with large or 
multiple tumours in a more extensive 
trial asking similar clinical questions.
in serum tumour markers, 
the results of surgery after 
chemotherapy, quality of life, 
and patients’ preferences about 
treatment. the investigators 
are collecting tumour tissue 
and blood for future molecular 
and genetic studies.
Rebecca Mister, SNAC and SNAC 2  
trials manager, and CTC’s head of 
site management
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LUNG CANCeR: HIGHLIGHT
how much involvement  
does an individual patient prefer?
the ctc has a tradition of research to draw out the individual 
preferences of patients in decision making about treatment—whether to 
undergo a treatment and how much involvement in the decision. this 
is especially important for patients with poor prognosis. for example, 
people with advanced lung cancer need to consider chemotherapy 
that will affect their quality of life but is not likely to cure their disease. 
patients with non-small-cell lung cancer vary more than their doctors 
in how they judge the worth of treatment. 
A recent study recruiting 98 patients from 16 sites and Australia and 
New Zealand has explored the preferences of lung cancer patients 
for participating in the decision making about their treatment.129 
Does an individual patient prefer an active, collaborative or passive 
role? understanding these individual preferences is important for 
their doctors to meet their expectations, to guide discussions about 
treatment recommendations, and to increase patient satisfaction.
Most patients preferred a collaborative role. those who preferred an 
active role demanded more of their chemotherapy treatment than the 
others; that is, they thought that chemotherapy would have to result in 
longer survival to be worthwhile. A patient’s preferred decision making 
role can change over time, some wanting more control and others less, 
as their illness progresses. the implications for oncologists are that they 
should consider each patient’s decision making preferences every time 
a treatment decision is made. 
this study was first brought as a concept by author Dr prunella blinman 
to an Australia & Asia pacific clinical oncology research Development 
(AcorD) workshop, where it was developed into a clinical study 
proposal for implementing by the Australasian Lung cancer trials Group 
and ctc. AcorD workshops are run by the Medical oncology Group of 
Australia, and currently chaired by Martin stockler, to educate health 
professionals in clinical trial design.
patient-preference studies such as this have used and extended methods 
originally pioneered by ctc’s John simes and Alan coates in the 1980s, 
which asked patients who had undergone a particular cancer treatment 
to judge its value to them. 
alTg
the ctc’s lung cancer trials 
are collaborations with the 
Australasian Lung cancer trials 
Group. the group aims to 
reduce the incidence, morbidity 
and mortality of lung and other 
thoracic cancers and improve 
the quality of life of patients, 
carers and families in Australia 
and New Zealand.
the collaboration is 
currently conducting trials of 
immunotherapy with new 
antibodies for non-small-
cell lung cancer (br.31) 
and mesothelioma (DreAM), 
and a trial of radiotherapy 
with an antibody for advanced 
non-small-cell lung cancer 
(NivorAD).
Ann Livingstone, associate oncology 
program manager for ALTG trials
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OnCOlOgy STuDIeS leaD TO 
perSOnalISeD TreaTMenT fOr paTIenTS
personalised cancer treatment—that is, treatment based on an individual’s 
specific molecular biomarker landscape—depends on a spectrum of research 
that includes clinical trials and laboratory testing. biological markers and 
genetic variants and mutations may predict the response of a patient to a 
particular treatment or forecast survival and thus represent an important 
part of choosing the right treatment for the individual patient.
the ctc and its collaborative groups now embed their cancer trials in 
a translational research spectrum that extends over laboratory analyses, 
clinical trials, and meta-analyses of combined data. in most of the trials that 
the ctc designs and coordinates, patients may choose to consent to their 
biological samples being used in research that benefits other patients and 
helps the design of future trials.
when predictive biomarkers in these samples have been identified and 
verified, this information can be used for genetic or molecular testing 
as part of screening patients before they are enrolled in a new trial. 
recent examples highlighted here are tActic (page 9)53 and icecreAM 
(page 9).159
ctc investigators apply statistical techniques to pooled data from 
completed trials to explore new targeted treatments 97 and evaluate 
predictors of disease progression.105 in some collaborative studies, the 
researchers have assayed samples collected in several similar high-quality 
completed trials and have linked results with pooled trial data to arrive at 
new insights and clinical applications; for example, the Her2 breast cancer 
study (page 18).96
the ctc is a member of, and works closely with, the virtual research 
consortium, sydney catalyst, the translational cancer research centre 
of central sydney and regional Nsw. sydney catalyst brings together 
outstanding teams of researchers and clinicians from over 20 leading Nsw 
institutions with the ability to undertake oncology research across the full 
continuum through basic biosciences, molecular biomarker discoveries, 
descriptive research, clinical trials, and implementation of best evidence-
based care into practice. 
in 2016, ctc researchers and their colleagues attended major international 
meetings and presented results and progress of various studies identifying 
prognostic markers or markers predicting individual responses to 
particular treatments. these included iNteGrAte, the co.17 and co.20 
gastrointestinal cancer trials, the NeoNAb breast cancer trial, and the 
cAtNoN and vertu brain cancer trials.
Mustafa Khasraw, clinical lead for 
neuro-oncology trials
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a potential predictive test for  
targeted breast cancer treatment
A recent study ctc study involving oncologists, statisticians and other clinical 
triallists has uncovered the value of a blood test to predict whether a specific 
targeted treatment for advanced breast cancer will be effective.96
some breast cancers are Her2-positive. Her2 (human epidermal growth 
factor receptor 2) is a protein on the surface of breast cells. High levels of these 
receptors can cause breast cancers to grow and spread. patients with invasive 
or advanced breast cancer routinely have biopsies that test their tumours for 
Her2, and their treatment is chosen accordingly. if the tumour is considered 
Her2-positive, the patient may benefit from a drug that blocks Her2, such as 
trastuzumab or lapatinib. if results are negative, this class of drugs might not 
benefit the patient.
A blood test is generally more convenient than a tumour biopsy. the new 
study examined whether Her2 protein shed by the breast tumour into the 
blood (serum Her2) might be useful for an alternative test. the research team 
exhaustively analysed data and blood results from nearly 2000 women in three 
trials of lapatinib treatment (versus chemotherapy alone or a placebo) for 
advanced breast cancer.
they found that patients with higher values of serum Her2 did better on 
lapatinib than those with lower values, but had worse outcomes than those with 
lower Her2 if they did not get lapatinib, reflecting the fact that untreated Her2-
positive tumours may progress more quickly.
these results are exploratory, and investigations of other drugs in this class have 
so far been inconsistent. However, the prospect of testing blood to predict the 
benefit of anti-Her2 treatment holds promise. 
Personal story
phIlIp hOgg:  
new CanCer 
TreaTMenT  
TargeTS IDenTIfIeD 
In labOraTOry 
STuDIeS
professor philip Hogg, chair 
of translational cancer 
research at ctc and sydney 
catalyst, has discovered 
a new type of chemical 
modification in proteins that 
appears to be important for 
all life forms. He has shown 
that the modification of 
allosteric disulphide bonds in 
proteins is related to cancer.
Allosteric disulphide bonds 
are being identified in 
many other biological 
systems such as blood 
coagulation, immunity and 
inflammation. phil is using 
his novel findings to develop 
innovative drugs targeting 
several of these bonds for 
new cancer therapies.
in 2016, he chaired the 
first international scientific 
meeting dedicated to this 
chemical modification in 
colorado, sponsored by 
the federation of American 
societies for experimental 
biology (fAseb), which 
represents over 125,000 
researchers in 30 scientific 
societies in the usA and 
around the world. the 
meeting is a significant 
milestone for phil and his 
research field.
Chee Lee, clinical lead for oncology studies, with Sally Lord, epidemiologist  
and research fellow with an interest in clinical testing
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Personal story
MyThIly SaChChIThananThan: 
COOrDInaTOr Of The vIrTual  
bIObank fOr braIn TuMOurS
i work at ctc as the senior project coordinator for brain 
cancer biobanking Australia, a consortium of brain cancer 
clinicians, researchers and biobankers who have joined 
forces to overcome the fragmentation and variable quality 
of brain cancer biobanking operations in Australia. 
we aim to provide researchers with the amount, quality 
and type of tissue and associated data they need to 
accelerate brain cancer research. it is a virtual biobank, 
networking independent biobanking operations Australia-
wide, leveraging existing systems to arrive at standardised 
procedures and protocols and a searchable online register 
to expedite access to samples. 
brain cancer banking Australia was founded by a consumer 
advocate, robyn Leonard, in 2015, with the goal of 
ensuring that all donated biospecimens are used for 
maximum health and scientific benefit. 
it has been rewarding to bring my background and 
experience in research and biobanking to help set up the 
network. i interact with various stakeholders and i am 
learning new things constantly. being part of coGNo and 
the ctc allows us to be connected to clinical trials research 
and potentially help facilitate translation of any promising 
preclinical research into clinical trials that can eventually 
lead to new treatments. 
Libby Cregan, in the CTC Oncology offices at Chris O’Brien Lifehouse
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CarDIOvaSCular reSearCh HIGHLIGHT: LIPID
focus on preventing heart attack and stroke
cardiovascular disease is still the leading cause of early death in Australia. 
Developing countries have been catching up, with increases in the prevalence 
of cardiovascular risk factors led by demographic changes. in Australia and 
elsewhere, better treatments mean that more people are living longer with 
heart disease. the burden of chronic heart disease is a national health priority 
and a target of ctc research into prevention and treatment. 
cardiovascular risk is known to be related to LDL cholesterol levels. over the 
past decade, the international cholesterol treatment trialists’ collaboration 
(coordinated by ctc and the clinical trial service unit at oxford) has published 
results of several major studies on cholesterol lowering with statin therapy and 
the subsequent reduction in heart attacks, strokes and other cardiovascular 
events. the collaboration has analysed data from 28 trials internationally, 
including 9014 LipiD patients. current evidence for the benefit of using statin 
therapy for prevention was reviewed in a Lancet article by the collaboration 
in 2016.39 in another study, statin therapy was shown to be less effective for 
patients with severe chronic kidney disease.36 
recently, public debate has arisen about whether there might be potential 
harms of statin treatment as well as benefits, such as respiratory conditions, 
fractures and parkinson’s disease. in response, in 2016, the collaboration 
published its formal plans for meta-analyses seeking definitive evidence of 
adverse events in 30 statin-therapy trials with about 200,000 participants.37
Another question now is whether even lower LDL cholesterol levels (less than 
1.0 mmol/L), attainable only with newer drugs, the pcsK9 inhibitors, can further 
reduce risk. this is being tested in several international mega-trials, including 
fourier, with 27,500 participants.155
long-term follow-up 
of heart patients shows 
statin therapy is safe
After a total of 16 years of follow-
up, ctc’s Long-term intervention 
with pravastatin in ischaemic 
Disease (LipiD) trial has shown 
clearly that the higher survival rate 
due to 6 years of statin treatment 
is sustained over a long period, 
mainly because of prevention 
of death from cardiovascular 
disease.63 Long-term follow-up 
also has the reassuring finding 
that treatment with statins is not 
related to any increase in any new 
cancer, or deaths from cancer or 
from other causes. 
the LipiD trial was a major early 
achievement of the ctc. in the 
early 1990s, the trial recruited 
over 9000 patients who had 
recently had a coronary event 
but who had normal cholesterol 
levels. these patients, from 
87 hospitals in Australia and New 
Zealand, were randomised to 
commence pravastatin or placebo 
and then followed up for 6 years. 
the treatment significantly and 
cost-effectively reduced mortality 
and major cardiovascular events. 
overall mortality was reduced by 
23% and death from coronary 
heart disease by 24%. clinical 
evidence from LipiD enabled 
subsidy for pravastatin treatment 
through the pharmaceutical 
benefits scheme and changed the 
Australian treatment guidelines.
Anthony Keech, CTC deputy director and head of cardiovascular research
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prevenTIng CarDIOvaSCular DISeaSe
CtC alum
TOM brIffa:  
reSearCh leaDer anD  
aDvOCaTe fOr CarDIaC 
evIDenCe TranSlaTIOn  
anD ServICeS
What do you do now?
 i am director of the health services and 
cardiovascular research in the school 
of population and Global Health at the 
university of western Australia, with adjunct 
appointments at the George institute and the south Australian Health 
and Medical research institute and other national health agencies.
i am a senior health researcher with specific expertise in clinical 
cardiovascular epidemiology, clinical trials, evidence translation 
and health services. coronary heart disease has a high disease burden 
in Australia, second only to cancer. the cost of repeat heart attacks 
in Australia runs into billions. people with coronary heart disease can 
reduce their risk of a heart attack or stroke with preventive lifestyle 
and drug therapies as part of a systematic program. this must be 
evidence based, tailored to the individual patient and sustainable over 
a lifetime. Hospitals and their rehabilitation teams, Gps, patients and 
health systems are all involved.
My work is built on data linkage. western Australia is unique in 
Australia in having had health data linkage since the 1970s, with the 
wA Data Linkage system formally established in 1995 and able to 
use de-identified health data for research.
i have spent 25 years examining trends and models of care in 
cardiovascular disease treatment and management. i am able to 
follow my interest in the prevention and treatment of cardiovascular 
disease and its translation into practice.
When were you at CTC?
My phD thesis, through the ctc, was completed in 1999. it was a 
randomised controlled trial of cardiac rehabilitation with an associated 
cost-effectiveness analysis. the cost-effectiveness analysis strengthened 
the case for rehabilitation to be routinely offered to all acute coronary 
syndrome survivors.
How did your CTC experience influence your career?
ctc developed my ability to conduct a methodological rigorous 
randomised controlled trial in an area that is still very relevant to 
my work today. i stay in regular touch with the ctc researchers.
After the 6 years of the trial 
finished, participants were 
all offered treatment with 
pravastatin, and most continued 
with it. During the years of 
extended follow-up, almost 
the same proportion of each 
group received statin therapy 
(about 85%).
the longer-term effects of statins 
on net clinical benefit had been 
questioned in public forums over 
the years, particularly in relation 
to cancer and other serious 
disorders. As part of the follow-
up study, the LipiD investigators 
particularly focused on cancers 
and, for further reassurance, also 
conducted a meta-analysis of the 
cancer data available from other 
similar statin trials. this meta-
analysis resulted in conclusions 
that allocation to pravastatin 
rather than placebo had no 
significant link with cancer 
mortality or cancer incidence, 
during the trials or the long 
period afterward.
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InTernaTIOnal MulTIfaCeTeD 
reSearCh In DIabeTeS
Diabetes mellitus, which is associated with elevated glucose levels, and also 
widespread disturbances in carbohydrate, fat and protein metabolism, is a 
major health problem in Australia and the rest of the world. Diabetes causes 
a death somewhere in the world every 6 seconds and a leg amputation every 
20 seconds. it is the commonest cause of working-age adult-onset blindness 
in the western world and a common cause of kidney failure, and at least doubles 
the risk of heart disease. 
Diabetes, including the common type 1 and type 2 forms, is an important area 
of clinical practice and also of ctc’s research, in the laboratory, with people 
with diabetes, and in advocacy and training the next generation of medical 
researchers. 
the ctc’s diabetes group, with its national and international collaborators 
and trainees approach this devastating disorder from multiple directions: 
laboratory research to advance the understanding of the molecular and genetic 
processes of insulin production;73,74,86 preventing the onset and progression of 
diabetes complications;101,143,169,183,208 clinical projects to advance insulin delivery 
for people with type 1 and type 2 diabetes,112,114,115,161,162 including the artificial 
or bionic pancreas;114,161 and in advocacy of access to insulin and its storage in 
disadvantaged regions.138,139. 
clinical study highlights in 2016 have included, first, closing of the reMovAL 
trial, which has tested the type 2 diabetes oral drug, metformin, added to 
insulin to protect people with type 1 diabetes against atherosclerosis and, 
second, commencing recruitment for fAMe-1 eye, to determine whether oral 
fenofibrate acts against the progression of eye disease in adults with type 1 
diabetes. A centre for research excellence in Diabetic retinopathy grant allowed 
progress in studies related to improving eye care in indigenous Australians. 
studies in type 1 and type 2 diabetes explored new molecular and biochemical 
markers that may predict diabetes complications.72,200,201 
Laboratory research in understanding the epigenetic regulation of insulin 
gene expression is being led by Anand Hardikar, who leads the islet biology 
and Diabetes group. other areas of research include identifying the molecular 
processes of insulin production, validating molecular biomarkers of diabetes 
progression and leading research in understanding the role of gut microbes in 
obesity and type 2 diabetes using cell culture and animal models.
these projects involve national and international teams of clinicians and 
scientists and trainees, from short-term summer students to postdoctoral 
fellows, and are funded by various non-profit agencies, including government, 
the fred Hollows foundation and the Juvenile Diabetes research foundation 
(international and Australia).
Alicia Jenkins, head of CTC’s  
diabetes group
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DIabeTeS anD ITS COMplICaTIOnS
adults with type 1 diabetes have  
shorter telomeres, thought to reflect 
accelerated ageing 
Genetic material (such as DNA) is contained in specialised 
structures—chromosomes— inside the nuclei of many 
body cells. telomeres are highly specialised regions at each 
end of a chromosome that protect them when cells divide. 
they are sometimes likened to the caps that prevent the 
ends of shoelaces from fraying. telomeres shorten each 
time a cell divides, until eventually, at a critical telomere 
length, the cell dies. telomere length is a marker of 
ageing. it has been shown that high blood sugar and 
blood pressure, smoking and body fat are associated 
with shorter telomeres. in diabetes, telomere length 
and accelerated ageing are closely related, and in some 
small studies shorter telomeres have predicted long-term 
outcomes such as death and kidney failure. telomere 
length can be measured in research laboratories and 
potentially in hospital laboratories in white blood cells, 
which are included in commonly taken blood samples.
A study by the ctc diabetes group and their colleagues 
comparing a group of people with type 1 diabetes and a 
control group without diabetes has shown that telomeres 
are relatively shorter in type 1 diabetes patients and, as 
expected, they are shorter in in older people with and 
without diabetes.72 However, in this study telomere length 
did not differ significantly between diabetes patients with 
long-term diabetes complications such as eye or kidney 
damage and those without complications. A relatively 
shorter telomere length was shown to be associated 
with some traditional risk factors for long-term diabetes 
complications, like age, male sex and diabetes duration, 
but not with body build, blood sugar control, blood 
pressure, smoking, kidney disease, inflammation or 
oxidative stress. 
this study had over 300 participants who had 
a particularly wide variety of carefully validated 
measurements of characteristics related to diabetes, 
such as blood pressure, blood vessel elasticity, blood 
sugar control, cholesterol levels, kidney function and 
novel markers of risk factors such as inflammation 
and oxidative stress. 
studies over time, where the measurements are repeated, 
is the next step to extend the results. if found to be 
clinically helpful, this telomere length assay could be 
established in clinical laboratories and used to predict 
outcomes for individual diabetes patients. other research 
is exploring lifestyles and drugs that may protect people 
against telomere shortening.
HIGHLIGHTS
Pancreatic Islet Biology
in 2016, the leader of the ctc’s 
Diabetes and islet biology group, 
Anand Hardikar, published a 
comprehensive textbook reflecting 
his international standing in the 
mechanics of insulin production.1 
the book covers genetic 
mechanisms of insulin production, 
development of embryonic stem 
cells, insulin regulation, and pancreas transplantation.
the book aims to educate young researchers who are 
starting a career in islet biology, senior researchers who 
want to understand fundamental aspects in different 
areas, and cross-disciplinary scientists interested 
in islet cell development; lineage commitment; 
cell differentiation, regeneration and function; the 
pathobiology of diabetes; and clinical replacement 
of pancreatic islet cells in people with diabetes.
contributors to the book’s 12 chapters come from 
leading basic science and clinical research groups around 
the world, and include ctc’s Alicia Jenkins, Andrzej 
Januszewski, wilson wong and Mugdha Joglekar.2,3
Diagram showing telomeres the ends of chromosome
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MaJOr prOgraM Of ClInICal TrIalS In 
neOnaTOlOgy anD perInaTal MeDICIne
the ctc neonatal team work with clinicians through global partnerships in 
areas of need, to improve the lifelong consequences of neonatal and perinatal 
disorders.
important in these partnerships are parents, family members and others with 
the experience of having a premature infant. they are welcome at the annual 
sydney international update on Advances in perinatal care, run by ctc and the 
wiNNer centre, and other interdisciplinary conferences and as partners and 
contributors in all aspects of clinical trials. they contribute their experience and 
views in the choice of research questions and the design and interpretation of 
neonatal trials. 
Neonatal trials have special challenges. they must often be surprisingly large 
to detect moderate benefits, and thousands of children may be needed to show 
a definite result. some disorders are rare, so accrual is drawn out. the effects of 
preterm birth may not unfold for some years, so long-term follow-up is needed 
to capture effects on physical, mental and social development.
the ctc neonatal group and wiNNer centre for Newborn and perinatal 
research advocate systemic and methodological improvements in the way 
clinical trials are conducted to keep them manageable and affordable. these 
strategies include embedding clinical trials in routine care, closer partnerships 
between clinicians and parents, use of high-quality point-of-care data, 
exploration of opt-out consent in low-risk comparative effectiveness research 
and the newly conceived ALpHA collaboration, which aims to advance large 
efficient perinatal trials of health outcomes assessment of 5000 to 50,000 or 
more participants, through international collaboration.
the protect trial began in 2016. this new trial brings the number of current 
neonatal trials to six, all large complex international studies, which will 
eventually recruit about 7000 patients, with total funding of over $15 million.
The health and future  
prospects of infants born 
before 29 weeks’ gestation 
are steadily improving, 
largely thanks to well 
organised clinical trials. 
Even so, many preterm 
or severely ill infants die 
or develop disabilities. 
CTC’s neonatal and 
perinatal trials are at the 
forefront in addressing 
the causes and 
promoting healthy 
survival through 
international 
collaboration.
Sarah Finlayson, elisabeth 
Coates and Rebecca Brown, 
with neonatal program 
manager, Alpana Ghadge
William Tarnow-Mordi, director of 
neonatal and perinatal trials
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a beTTer fuTure fOr newbOrnS
higher oxygen saturation levels  
improve survival of very preterm infants,  
without increasing disability or blindness
in 2016, the combined results of the Australian and uK 
boost ii trials in 1135 infants born before 28 weeks 
gestation were published in the New England Journal 
of Medicine.174 
infants born before 28 weeks have immature lungs and 
often require supplemental oxygen. before this evidence, 
neonatal specialists targeted oxygen between 85% and 
95%. it was known that higher levels could cause death 
and disability but also carried a risk of eye damage. it was 
thought that the lower range might reduce the risk of eye 
damage from retinopathy while being effective against 
the risk of other disabilities. 
Data from boost ii in Australia with 1135 infants and 
boost ii in the uK with 973 infants were combined. 
in the combined analysis, 48.1% of the infants in the 
lower-target group and 43.1% in the higher-target group 
had died or had a disability by the age of 2 years. this was 
a statistically significant difference. of every 28 infants 
allocated to the higher rather than the lower oxygen 
target, there was one extra survivor.
NeOProM combines BOOST II data  
in a fresh analysis of more data from five trials
Data from patients in these trials is being combined with 
data from similar canadian and us trials in the prospective 
NeoproM meta-analysis. this study is producing evidence 
from newly analysed data from 4965 patients. 
preliminary results were presented by Lisa Askie at the 
congress of the european Academy of paediatric societies, 
Geneva, in october, and at Hot topics in Neonatology in 
washington in December. for every 1000 infants aged 
18 to 24 months, a higher oxygen saturation target of 
91–95% compared with a lower oxygen target of 85–90% 
made no difference to the rate of death or major disability, 
but resulted in 28 more survivors, 22 fewer babies with 
necrotizing enterocolitis (a severe gastrointestinal 
emergency) and 40 more babies having treatment for 
retinopathy of prematurity, with no increase in blindness.
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karen SIMMer aO:  
reSearCh leaDer 
In neOnaTOlOgy 
COllabOraTIng 
wITh CTC
i am the inaugural 
professor of Newborn 
Medicine at the university 
of western Australia and 
co-director of the NHMrc 
centre of research excellence for preterm infants 
and the director of the busiest neonatal intensive 
care unit in Australia. we have a successful record 
of recruitment to neonatal trials. i lead a large 
multidisciplinary team and have developed 
extensive clinical and research networks in this 
area.
one of my main areas of research interest is 
neonatal infection and prevention of the serious 
consequences of infection and inflammation. 
these include white matter injury and 
neurodevelopmental impairment. i am leading 
the protect trial, a major new collaborative 
project coordinated by ctc, starting in 2016 
with funding from a NHMrc project grant of 
2.9 million. 
protect is investigating whether pentoxifylline 
can improve long-term outcomes (measured at 
2 to 3 years of age) of very preterm infants with 
late-onset sepsis or necrotizing enterocolitis. we 
are recruiting 1800 infants born before 29 weeks’ 
gestation in Australia, NZ, taiwan, singapore and 
canada. they will be allocated to intravenous 
pentoxifylline,an anti-inflammatory drug, or 
placebo, as adjunct to antibiotics.
My other main research interest is the effect of 
early nutrition, especially human milk, on the 
health and development of infants. 
placental transfusion for preterm infants:  
first short-term results
Advances in the treatment of premature infants have 
already reduced the incidence of death and disability. 
An unanswered question in neonatology is the best time 
to clamp the umbilical cord. very premature infants are at 
risk of later disabilities, particularly neurological problems 
and infections. the standard procedure in Australia is 
to clamp the cord immediately to allow the infant and 
mother to be cared for efficiently, but delay in cord 
clamping might increase the volume and flow of blood 
in the infant, reducing the need for blood transfusions, 
and might have other benefits. Another approach to 
increasing the infant’s blood volume is milking the cord 
of placental blood. the optimum procedure has not been 
guided by trial evidence, particularly for infants born by 
caesarean section.
the Australian placental transfusion study is comparing 
immediate and delayed cord clamping. the trial has 
recently completed recruitment of over 1600 infants 
born before 30 weeks’ gestation. the trial was designed 
to establish whether obstetricians and midwives could 
reduce the risk of death and disabilities in children born 
early by delaying clamping the umbilical cord for a minute, 
thus allowing more placental blood to flow into the 
infant. these trial participants will be followed up over 
3 years.
in a substudy of the trial using data now available, the 
investigators determined whether delayed cord clamping 
resulted in better blood flow in the first day of life.149 the 
main measure, blood flow into the heart, was found to be 
similar in both groups of infants, overall and in subgroups. 
there was no difference between the groups according 
to whether it was a vaginal or caesarean birth. the study 
raised some concerns about the feasibility of delayed cord 
clamping for very premature infants, as in some cases, 
the attending clinician had to abandon this practice to 
resuscitate the infant. the final outcomes of Apts and 
similar trials are awaited before any changes to obstetrical 
guidelines can be considered.
the substudy has attracted attention, and the results were 
highlighted by an editorial when published in 2016 in the 
Journal of Pediatrics. 149
Personal story
helen lIley:  
reSearCh 
leaDer In 
neOnaTOlOgy 
COllabOraTIng 
wITh CTC
i am a practising 
neonatal paediatrician 
and a research 
physician collaborating 
with ctc on clinical trials. i undertook paediatric 
training in Auckland and the children’s Hospital 
in boston, and first became involved in research 
at the university of california, san francisco. 
while my early scientific interest was in the cell 
biology of lung and blood vessel development, 
my current clinical research, including multicentre 
trials, is to improve the outcomes of infants 
who need resuscitation at birth and subsequent 
neonatal intensive care.
in my current collaboration with the ctc, i am 
chief investigator of pAeAN, a trial recruiting 
300 infants with high risk of brain damage due to 
low oxygen or blood supply to the brain at birth. 
we are randomly allocating infants already on 
whole-body cooling treatment to either placebo 
or erythropoietin. erythropoietin is best known 
for stimulating production of red blood cells, but 
it also has protective effects on the brain. the 
children in the study will be assessed at two years 
of age.
Aside from the clinical trials, i also undertake 
research into aspects of training clinical teams 
in neonatal resuscitation and monitoring with 
professor penelope sanderson, an expert in 
safety-critical workplaces. our projects have the 
general aim of optimising the performance of 
doctors, midwives and nurses working together 
to give frail infants a better start. 
APTS SUBSTUDY
26 
InTegraTIng TrIal evIDenCe fOr pOlICy anD praCTICe
InTegraTIng TrIal evIDenCe fOr pOlICy anD praCTICe
The best unbiased evidence 
on a particular aspect of 
clinical care is generally 
found by a systematic review 
of available research results.
the systematic reviews and Health technology Assessment group at ctc 
undertake work to integrate trial and other evidence into a foundation for 
effective decision making in health policy and clinical practice.
their projects include reviews for the international cochrane collaboration, 
mainly in breast cancer, and reviews of new technology where effectiveness 
or suitability for funding has to be established.228–233 the group also has 
a reputation for its individual participant data meta-analyses answering 
important clinical questions across a range of areas such as maternal and 
child health, including the NeoproM (Neonatal oxygenation prospective  
Meta-analysis) and pAris (perinatal Antiplatelet review of international 
studies) projects, which are completed but still raising new research  
questions.8
ctc is represented on the test evaluation working Group of the european 
federation of clinical chemistry and Laboratory Medicine, which recently 
developed a strategy and checklist for appropriately using tests for new 
molecular and genetic biomarkers in clinical practice.124
Systematic reviews and economics evaluations  
assist in government decision making and policy
the ctc undertakes systematic reviews and economics evaluations under 
contracts with the commonwealth Department of Health and the National 
Health and Medical research council. 
the group develops review protocols, critiques submitted evidence and 
conducts independent reviews to assist the Medical services Advisory 
committee make decisions on new listings for the Medical benefits schedule. 
in 2016, this work spanned health areas that included cardiology, oncology,228,229 
gastroenterology, dermatology and prenatal screening.232,233
this group also reviews evidence and provides methodological expertise to 
the NHMrc, which develops health guidelines for Australia. this work often 
addresses broad public health questions.231
Lisa Askie, head of CTC’s Systematic 
Reviews and Health Technology 
Assessment group and leader of 
international meta-analyses in 
neonatology
Mark Ayson, Samara Lewis, 
Saskia Cheyne and Blaise 
Agresta, who evaluate  
evidence on new technologies 
and treatments for government
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lukaS STaub: 
SenIOr reSearCh 
fellOw generaTIng 
evIDenCe fOr uSIng 
new MeDICal TeSTS
What do you do now?
starting in 2017, i will be 
returning to ctc to work 
with sally Lord in the 
epidemiology and test 
evaluation group, where we develop research methods for 
the evaluation of new medical tests. we do this because a 
new diagnostic test, even if it is accurate, must be evaluated 
for its ability to change clinical management and ultimately 
improve outcomes before it can be introduced into practice. 
the pathway from a new test to better health for patients 
can be complex, and clinical trials of the process are not 
always feasible.
i am also part of a health economics project with rachael 
Morton on the cost-effectiveness of screening migrants to 
europe for infectious diseases, and other test-related studies.
When were you at CTC?
i am a medical doctor primarily interested in research. i came 
from switzerland and was a ctc phD research student from 
2008 to 2011. My thesis was entitled Medical test evaluation— 
evidence beyond diagnostic accuracy. its aim was to advance 
the evidence base of medical test evaluation by improving the 
selection, design and interpretation of studies that investigate 
different test results along the causal pathway linking testing 
with patient health outcomes.
How did your CTC experience influence your career?
i remember many inspiring discussions with John simes 
during which i learned to understand the complexities around 
the evaluation of medical tests. His clinical expertise ensured 
that my work was always based on real-world examples and 
applicable to daily practice.
My phD studies fitted well with my continuing interest in 
diagnosis of causes of low back pain, because symptoms 
and radiological findings can be contradictory. i was part of 
a collaboration that identified a new sign to detect lumbar 
spinal stenosis. this work has been continuing in recent years 
through my tenure as a research fellow at the institute of social 
and preventive Medicine, university of bern. 
fluoride in public health
over the past two years, the ctc 
has undertaken an evaluation of 
evidence on the health and dental 
effects of water fluoridation for 
the National Health and Medical 
research council. the review 
updated a previous review of the 
evidence on the health effects of 
water fluoridation.230,231
programs of fluoridation of the 
water supply were first introduced 
in Australia half a century ago 
to reduce tooth decay, especially 
among children. the NHMrc last 
reviewed the evidence on risks and 
benefits of the practice in 2006, and 
decided to update the evidence in 
2012 following ongoing community 
concerns regarding potential effects 
on health, and in line with its policy 
on maintaining currency of the 
NHMrc’s evidence base.
ctc reviewers worked with a 
reference group comprising experts 
in the fields of public health, oral 
health, epidemiology, child health, 
toxicology, cancer, bone biology, 
neurodevelopment, Aboriginal 
and torres strait islander health, 
water management and health 
ethics. the work was multifaceted, 
and included undertaking several 
evidence reviews, collating evidence 
submitted in a public consultation 
process and assisting in production 
of a public summary document. 
the evidence evaluation concluded 
that fluoridating water helps to 
reduce tooth decay, by protecting 
against damage and helping with 
the repair of teeth. the review found 
no evidence that water fluoridation 
at current Australian levels causes 
health problems. 
HTA: HIGHLIGHT
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Commitment to trusted evidence for  
informed decisions on breast cancer
for reputable evidence on questions of health care, the leading information 
source is the international cochrane Library. the National Health and Medical 
research council in canberra supports the cochrane Library so that all 
Australians can access unbiased, high-quality, evidence-based health care 
information at no cost to themselves.
the cochrane breast cancer Group, which coordinates and leads the review 
and publication of evidence from breast cancer research, has been based at ctc 
since 1996. on its 20-year anniversary the group acknowledged its founders, 
iain chalmers, Mike clarke, Kay Dickersin, Davina Ghersi, Alessandro Liberati, 
chris silagy and John simes, its early funders, and Martin stockler and Nicholas 
wilcken, who developed major practice-guiding cochrane reviews on metastatic 
breast cancer. the efforts of all these people and their successors have led to 
better treatment and internationally used treatment guidelines for people with 
breast cancer. 
the group now includes over 800 volunteers from diverse backgrounds: 
consumers, methods experts, statisticians, surgeons, radiation and medical 
oncologists, and guideline developers. the cochrane breast cancer Group 
pioneered patient involvement across the board, inviting consumers to be 
authors, editors and peer reviewers since 1996. 
the cochrane breast cancer Group, like cochrane generally, does not seek or 
accept any commercial funding. they have been funded by the National breast 
cancer centre (Nbcc), the Department of Health and Ageing, the National 
breast cancer foundation, the us Department of Defense and the NHMrc.
An important review of evidence in 2016 examined research on radiotherapy 
regimens, and found that higher doses of radiotherapy in fewer treatment 
sessions was as effective as and less toxic than the conventional 25 to 30 
treatments. this new evidence will be incorporated into clinical guidelines and 
will be particularly beneficial for patients living in remote and regional areas.
COCHRANe BReAST CANCeR GROUP
australian new Zealand 
Clinical Trials registry: 
for better health and 
better research
the Australian New Zealand 
clinical trials registry (ANZctr) 
continues to provide a valuable 
service for registration of national 
and international clinical studies. 
in 2016, registry staff at ctc focused 
on spreading the word about the 
importance of trial registration and, 
improving the website to make it 
simpler for users to register their trials 
accurately and keep their records up 
to date. enhancements in website 
functionality include automated 
checks and reminders and improving 
the search function. 
the ctc’s ANZctr group have 
been actively engaging with the 
research community on the value of 
trial registration and sharing clinical 
data via presentations by Ailsa 
Langford and Kylie Hunter to various 
Australian groups and at the annual 
cochrane colloquium in seoul. these 
presentations have also explained the 
processes of how to register studies. 
ANZCTR
Melina Willson, managing editor for the 
Cochrane Breast Cancer Group

Between 2005 and  
the end of 2016,  
13192 trials were registered  
on the Australian New  
Zealand Clinical  
Trials Registry
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DavIna gherSI:  
SenIOr prInCIpal  
reSearCh SCIenTIST  
anD SenIOr aDvISOr
What do you do now?
At the National Health and Medical research 
council (NHMrc) in canberra i provide 
advice and support across the agency 
on matters associated with creating and 
translating research evidence. NHMrc is the 
leading expert body for developing and maintaining individual and 
public health standards. 
i believe that those engaged in health and medical research have a 
moral responsibility to conduct their investigations in accordance 
with sound scientific principles, and to report their results completely, 
honestly and transparently.
My role is an opportunity to make a real difference and improve the 
health of Australians through doing what i can to facilitate functioning 
working relationships between researchers and decision makers.
Australia is fortunate to have strong research governance and 
regulatory systems to ensure the integrity of research. NHMrc is 
uniquely positioned to bridge gaps between research, policy and 
practice and has great potential to accelerate translation of research 
evidence into better clinical decision making.
i am also an adjunct professor with ctc.
When were you at CTC?
i worked at ctc from 1992, initially as a cancer trial coordinator. Later, 
when i was head of systematic reviews and Health care Assessment, 
i started a phD, completed in 2007 while i was at the world Health 
organisation in Geneva, where i established the international clinical 
trials registry platform and fostered the relationship between the 
wHo and the cochrane collaboration.
My thesis was on issues in the design, conduct and reporting of 
clinical trials that influence the quality of decision making. research 
transparency, clinical evidence and the ethical translation of research 
into practice have been long-standing interests. 
How did your CTC experience influence your career?
My supervisor, John simes, who was a leader in advocating research 
transparency, had published on publication bias as early as the 1980s. 
we worked together on evidence reviews and editorial responsibilities 
for the cochrane breast cancer Group and setting up the Australian and 
New Zealand clinical trials registry, projects that were an ideal basis for 
my later achievements at the wHo and in government.
the registry improves the efficiency 
and value of Australian clinical trials 
research by helping to increase trial 
participation and showing the current 
status of clinical research. it allows 
policy makers to identify potential 
gaps between current trials research 
activity and health priorities.
for the public, registration of all 
clinical trials is important to health, 
as it is a way of disclosing all current 
research involving humans. it enables 
everyone to know what research is 
being done and whether any results 
might be missing from published 
science.
in 2016, the ANZctr registered 
over 1400 Australian or New 
Zealand studies and almost 
300 internationally run studies, 
144 each month on average. 
this was a significant increase 
in activity on previous years. the 
registry has continued its partnership 
with Australian clinical trials and 
Australian cancer trials, providing a 
direct feed of trials for their websites.
Slavica Berber and Kylie Hunter,  
staff of the Australian New Zealand  
Clinical Trials Registry
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regular monitoring of people at high risk of melanoma saves lives and 
reduces costs.
About 10,000 people in Australia are at very high risk of developing 
melanoma because of genetic predisposition or because they or their 
family have a history of previous melanoma. 
According to the clinical guidelines, they should be monitored regularly, 
so that any new melanomas will be picked up at an early, curable stage. 
on the other hand, monitoring skin lesions can lead to overtreatment 
and is time consuming for patients and clinics and requires highly 
trained staff. 
A study by ctc’s head of health economics, rachael Morton, with the 
school of public Health and the Melanoma institute Australia, has 
analysed this balance. they found that surveillance in a specialised 
clinic is both less expensive and more effective than standard care.194 
Melanomas were detected earlier, so less extensive surgery was needed. 
Also, close expert monitoring allowed the clinicians to better judge 
which lesions could be left alone, resulting in less excision biopsies. 
the average saving compared with standard care was about $7000 per 
patient.
the high-risk melanoma clinic was started up by the sydney Melanoma 
Diagnostic centre and Melanoma institute Australia with funding 
from the cancer institute Nsw. its methods of 6-monthly systematic 
surveillance with expert clinicians using digital dermatoscopy and total 
body photography were known from previous studies to be effective 
in detecting melanoma early. the investigators of this study wanted to 
find out if they were also cost-effective. they obtained evidence of the 
costs and benefits for 500 clinic patients and compared these with data 
on the standard care received by other Australian patients, who were 
identified from population health data and matched for melanoma risk.
Rachael Morton, director of health economics
HIGHLIGHT: MeLANOMA MONITORING
Proven new health-care 
treatments must be shown 
to be value for money before 
they are put into practice, 
whether they are publicly 
or privately funded.
Economic evaluations have 
long been integral to CTC’s 
trials and systematic reviews 
of evidence.
economic evaluation for 
better decision making
economic evaluation is incorporated 
into clinical trials when evidence 
of cost-effectiveness is needed or 
is likely to help decision making 
(that is, whether the intervention is 
cost-effective or not cost-effective); 
when the intervention is known 
to be expensive; or when the 
intervention affects quality of life.
economic evaluation also includes 
preference studies, which answer 
questions about patient, clinician 
or community preferences.189–191 
these studies can inform the design 
of new interventions, prevention 
strategies or diagnostic tests used 
in trials and advise on incentives 
or reimbursement in health policy.
the health economics group 
leads methodological and applied 
research in the area of health 
equity, with a focus on the financial 
impact of cancer,44 especially 
melanoma,42,43,111,165,194 and chronic 
kidney disease125–128,131,177,192,197,204 
on individuals and households. 
in addition, the group is currently 
investigating the ways in which value 
of information (voi) analysis can 
inform trial design and health policy 
decision making.
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New concepts for trials are usually proposed by clinicians or groups of clinical 
investigators. through clinical experience and contact with patients they know 
where new treatments need solid evidence arising from testing in trials. ctc 
has the range of sophisticated skills and fully formed processes for turning 
ideas into functioning trials. when new concepts are proposed by trial groups, 
biostatisticians develop the optimal trial designs most likely to result in the 
study delivering the best evidence as to the benefit of the proposed therapy. 
the biostatisticians are the methodological engines, translating trial concepts 
into workable projects that answer clinical questions in a scientific way.
ctc statisticians most often work on the ctc’s flagship trials, which test 
new therapies in many types of cancer, cardiovascular disease, diabetes and 
neonatal disorders.
biostatisticans also apply their expertise to clinical research in a wide range of 
medical specialties involving external collaboration. they join with national 
and international groups to play a part in designing, analysing and reporting 
trials which are efficient and methodologically rigorous. examples are 
recent achievements in oncology,52,57,185 radiation oncology,51,144,182 medical 
specialist training,184 indigenous health,151 infection,41 and osteoporotic 
spinal fractures .38
An article on a new way of delivering radiation to secondary liver cancers was 
considered one of the important papers in that specialty for 2016. this was the 
subject of the phase 3 sirfLoX trial, conducted as a partnership of international 
oncologists and the company that manufactures the treatment, with the 
analysis of results guided by ctc.57 the treatment, called selective internal 
radiation therapy, uses tiny radioactive spheres, injected via an artery to flow 
to the small blood vessels in the liver. the radiation did not affect or reduce 
any cancers elsewhere in the body, but in the liver it enhanced the effect of 
standard chemotherapy. 
 Val Gebski, head of biostatistics
bIOSTaTISTICIanS help Turn IDeaS InTO wOrkIng TrIalS
Below: Adrienne Kirby, senior CTC biostatistician, with Professor Ian Marschner 
At right: Rachel O’Connell, senior biostatistician
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CtC alum
anDrew MarTIn:  
frOM aCaDeMIa TO  
InDuSTry anD baCk
What do you do now?
After several years of postdoctoral 
work in pharmaceutical organisations 
i returned to academia to my current 
appointment at ctc. 
Here, i provide direction on study 
design and conduct, data analysis, and 
the interpretation and dissemination of results across national 
and international projects, mainly in oncology and perinatal 
medicine. i also develop course material for, coordinate, and teach 
trial methods and decision analysis, and supervise and mentor 
university staff and students. recent postgraduate students have 
explored questions about the treatment of latent tuberculosis, the 
cost of anticancer therapies, the clinical significance of treatment 
effects, the role of geriatric assessment in treatment decisions in 
oncology, and the effect of nicotinamide on skin cancer biology. 
in the pharmaceutical industry i directed statistical aspects of 
international programs in which candidate drugs or devices 
in the company’s pipeline were taken from discovery through 
to regulatory approval and mainstream use. companies have 
resources to fund specialised teams and bespoke systems to drive 
this process. Academic research has a much broader focus as to the 
types of interventions that receive attention, research objectives, 
and ways of getting the work done.
When were you at CTC?
My phD was awarded when i was at ctc in 2000. it addressed 
the problem of how to measure aspects of quality of life and distil 
these into a valid overall index that can be formally combined 
with survival and financial cost to evaluate trade-offs and facilitate 
decision making.
How did your early CTC experience influence your career?
i learned to think strategically about research design and its 
implementation, and about how to present research to make 
it readily accessible to others. i routinely apply these ideas when 
specifying study designs and statistical methods and explaining the 
meaning of results. communicating this information to  
non-statisticians can be challenging because of its technical nature. 
i apply the knowledge i’ve gained to deal with this challenge when 
teaching, collaborating with clinical investigators, preparing grant 
applications, and preparing publications.
in other projects, ctc biostatisticians 
take time to meet with researchers 
at hospitals and universities in 
sydney at regular intervals to see 
projects through to completion. their 
recent projects have included a wide 
variety of clinical areas, including 
cancers,67–69,102,133 especially skin32,33 
and gastrointestinal cancer,11,24,25,142 
neurology,92,147 allergy,70,98,130,173 
obstetrics,19,80,81,203 emergency 
medicine,89,123,163 diabetes,91,100 
psychiatry,20,21 and infection.12,27,90,148
Keeping abreast of the latest 
approaches to trial design has the 
biostatisticians reaching in many 
directions. they teach postgraduate 
students in university degrees and 
other health professionals in short 
courses and masterclasses. innovative 
methodology is developed, especially 
by ctc phD students and their 
supervisors,49,157 to eventually be 
applied to trials and other clinical 
research at the ctc and elsewhere.
elizabeth Barnes, biostatistics research 
fellow with administrative officer, 
Vanessa Cochrane 
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krISTy  
rObleDO: 
bIOSTaTISTICIan
engaging people 
with statistics is a 
difficult task. our 
statistics department 
is involved in a wide 
range of statistics 
teaching. 
we teach postgraduate students in public health, 
biostatistics and clinical trials programs and 
other health professionals in our workshops and 
masterclasses.
one that i have been part of in the past five years 
is a statistical workshop for trainee radiation 
oncologists. each year, we run an interactive 
one-day workshop, alternating workshop A and 
workshop b. Attending these workshops gives the 
trainees ‘sMArt points’. it’s part of their program 
that gives them the skills to appraise evidence and 
understand and participate in oncology-related 
research.
Different trial methods are addressed in each of 
the workshops with short didactic talks, followed 
by small group sessions that are led by facilitators 
(radiation oncologists with trials experience). 
As one of two statisticians at the workshop, my 
role is to give several talks over the day, and then 
to rove around the groups to assist with any 
questions. 
the day always has many questions raised, equally 
from the trainees and the facilitators! this has 
become one of my favourite teaching activities, 
and i think i learn just as much as some the 
trainees in how to articulate concepts in multiple 
different ways. 
Comprehensive education in 
clinical trials through postgraduate 
degrees and short courses
ctc offers training for people with a broad range of needs 
related to clinical trials. for those requiring a recognised 
postgraduate qualification for working in clinical trials, 
the Master of clinical trials research delivers solid 
understanding and the necessary skills to design and lead 
trials. the Master of biostatistics is a multi-university 
program to train professional biostatisticians. for 
those wanting an introduction to trials, without formal 
accreditation, the masterclasses in trial methodology 
and conduct give an overview, provided by ctc experts, 
over a week. other intensive short courses are offered 
by ctc faculty on specialised areas of scientific and 
clinical research.
postgraduate study
Master of Clinical Trials
As health care and health research become more closely 
intertwined, many health professionals need skills and 
knowledge to plan and conduct clinical trials in their area 
of expertise. 
the ctc developed its postgraduate course at the 
university of sydney in response to this need. it covers 
research methods, clinical trials literature and the 
clinical trials process, including design, regulations, 
and statistical and ethical considerations. the program 
is delivered online, including lectures, discussion forums 
and supplementary notes.
students not wishing to immerse themselves in the 
full master’s course have the opportunity to qualify 
for a graduate diploma or graduate certificate. the 
postgraduate program is coordinated by Adrienne Kirby, 
val Gebski and Anthony Keech.
currently, about 25 students join the course each year. 
eDuCaTIOn
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Short courses
Concept development workshops
ideas for new clinical trials come from patients, practising 
clinicians, scientists, and others who identify gaps in 
research evidence. promising trial questions can be 
workshopped into structured research plans at ctc’s 
popular one-day concept development workshops, 
held several times a year. 
Methodological experts from the ctc provide 
information, advice and guidance on how to develop a 
concept outline from an initial idea or scientific question. 
the day covers specifying a suitable aim, objectives, 
sample size, population, interventions, randomisation, 
study design, outcome measures, analysis plan and 
funding strategy, as well as further tips and hints on 
developing the proposal into a funding application 
or full protocol.
ctc faculty have long experience in the full lifecycle of 
a clinical research project: clarifying the idea; protocol 
development, ethics issues, obtaining finance, budgeting, 
research design, operations, results analysis, and 
reporting.
these workshops are provided at low cost, not for profit, 
as a contribution to building skills and knowledge to 
advance public-good clinical trials in Australia. 
Masterclasses in clinical trials
Masterclasses in how to plan, develop and manage 
clinical trials feature the core skills of ctc faculty 
developed over 28 years of experience and over 
180 clinical trials conducted. in 2016, ctc held 
masterclasses for professionals in various clinical areas 
who came to learn about trials operations, design, 
methods, conduct and interpretation.
Introduction to economic evaluation in health
Health economics is an increasingly important feature 
of health systems and research. economic studies focus 
on the equity, efficiency, costs and benefits of new and 
existing health care. ctc conducted a course in the 
fundamentals of economic evaluation in April 2016. it 
covered measuring and valuing resource use and costs, as 
well as outcomes, such as survival and utility-based quality 
of life. it placed economic analysis in the framework of 
health technology assessment and policies for national 
funding.
corresponding with the broad application and increasing 
importance of health economics to research, it attracted 
a diverse student group: clinicians, marketers, managers, 
advisers and financiers, from academia, government, 
hospitals and the pharmaceutical and insurance 
industries. the course will be offered annually.
Rachael Morton, director of health economics
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Alicia Jenkins, head of CTC’s diabetes group and co-convener of 
the diabetes and vascular disease masterclass
The diabetes and vascular disease masterclass
Short courses 
Diabetes and vascular disease masterclass
the ctc’s popular annual diabetes and vascular disease masterclass for clinicians 
was again held in 2016 in Melbourne. the program, convened by Anthony 
Keech and Alicia Jenkins, included case studies attracting lively debate and input 
from the panel and audience, especially discussions on depression in diabetes, 
palliative care in end-stage renal disease and gestational diabetes. this year’s 
lectures included a focus on recent molecular discoveries.
 ‘It is the best and most interactive meeting of the year.’ 
‘…valuable opportunity to see other perspectives in diabetes care 
and vascular disease’ 
‘As a rural physician, opportunities to interact with colleagues from 
across the specialities are few. This was a fantastic meeting with a 
very nice balance of science and clinical medicine’
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eDuCaTIOn
Intensive personal training in molecular biology
Mugdha Joglekar, 
Anandwardhan 
Hardikar, Wilson 
Wong and Andrzej 
Januszewski 
biostatistics Collaboration 
of australia
the biostatistics collaboration of Australia (bcA) is 
a consortium of biostatistical experts from around 
Australia with representatives from universities, 
government and the pharmaceutical industry who 
have combined to offer a national (and international) 
program of postgraduate courses via an alliance of 
universities.
the bcA program is delivered entirely by distance by 
consortium universities and administered from the 
ctc. over 350 students are enrolled, 170 of them 
new in 2016, and on graduation will contribute to 
solving the shortage of well qualified biostatisticians in 
Australia and elsewhere.
in 2016, ctc’s Diabetes and islet 
biology Group conducted a 6-week 
structured intensive personal training 
program for six overseas students 
in molecular markers of disease, 
from cell and tissue culture (‘Life in a 
dish’) to next-generation sequencing 
modules (‘Discovering the unknown’). 
this course was conceived, designed 
erica Jobling, Biostatistics Collaboration of Australia 
(BCA) executive officer
performance at the end. past 
participants have mainly been 
students of research collaborators 
in the Middle east, europe or Asia, 
although anyone is welcome to apply.
students benefit from the renowned 
expertise of professor Hardikar and 
the Diabetes and islet biology group 
generally. 
and directed by Anand Hardikar and 
co-directed by Dr Ammira Akil from 
sidra research centre and cornell 
university in Doha. it has become an 
annual activity.
the course consists of comprehensive 
practical lab-based training and 
seminars, with weekly exams 
and a certificate of training and 
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CurrenT CTC TrIalS
TRIAL PARTICIPANTS TARGeT ACCRUAL
Neonatal disorders
Current trials
LeAp: Lactoferrin evaluation in anaemia in pregnancy pregnant women with anaemia 900 19
CTC-led study
Lift: Lactoferrin infant feeding trial infants born weighing under 1500 g 1100 1073
CTC-led study
pAeAN: preventing adverse outcomes of neonatal hypoxic ischaemic 
encephalopathy
Newborn infants with signs of brain damage 300 21
CTC-led study
protect: can pentoxifylline improve long-term outcomes in 
preterm infants with late-onset sepsis or necrotizing enterocolitis? 
Neonates born before 29 weeks’ gestation 1800 7
CTC-led study
torpiDo2: targeted oxygenation in the respiratory care of 
premature infants at delivery: effects on developmental outcome
Neonates born before 29 weeks’ gestation 1200 9
CTC-led study
Trials in follow-up
Apts: Australian placental transfusion study Neonates born before 30 weeks’ gestation  1600 1633
CTC-led study
Cardiovascular disorders
Trials in follow-up
fieLD: fenofibrate intervention and event lowering in diabetes patients with type 2 diabetes 8000 9795
CTC-led study
Diabetes
Trials in start-up
Hybrid closed-loop study: adult Adults aged 25–70 with type 1 diabetes 120
St Vincent’s Hospital Melbourne, JDRF Australia, Medtronic, CTC
Hybrid closed-loop study: paediatric young people aged 12–24 with type 1 diabetes 160
Princess Margaret Hospital Perth, JDRF Australia, Medtronic, CTC
Current trials
6-month closed loop insulin pump 
CTC, St Vincent’s Hospital, Melbourne, and Telethon Institute study
Adults and youth with type 1 diabetes 120 adults;  
150 youth
e-preDice: early prevention of diabetes complications in people with 
hyperglycaemia in europe and Australia
Adults with hyperglycaemia 3000 404 
International study, BIONE and CTC
fAMe1-eye: fenofibrate and microvascular events in type 1 diabetes 
CTC-led study
Adults with type 1 diabetes and nonproliferative 
retinopathy
450
t4DM: efficacy of adding testosterone to a lifestyle program to 
prevent progression to type 2 diabetes
Men with prediabetes and low testosterone 1500 946
University of Adelaide and CTC study
reMovAL: effects of metformin added to insulin on atheroma 
progression 
Adults with type 1 diabetes at risk of 
cardiovascular disease
105 (ANZ); 
450 (int.)
105 (ANZ);  
450 (int.)
University of Glasgow and NHS-led, and CTC study
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Trials in follow-up
2-week closed-loop insulin pump in home study Adults and youth with type 1 diabetes 60 
CTC, St Vincent’s Hospital, Melbourne, and Telethon Institute study
teAMsnet: using internet and mobile technologies for coordinated 
diabetes and heart 
indigenous people from remote and rural 
Australian communities
600 600
University of Melbourne, Fred Hollows Foundation, AMSANT, CERA, 
CTC study
Oncology
Trials in start-up
Most: cancer Molecular screening and therapeutics patients with advanced solid cancers and available 
tumour tissue
1000 43
 Addendum 1: palbociclib patients with mutations in rb pathway 16 1
 Addendum 2: durvalumab plus tremelimumab enrolled patients with no actionable mutations 64 2
CTC and Kinghorn Centre study
Current trial
cannabis ciNv: pilot and definitive trials of cannabis extract for 
prevention of secondary nausea and vomiting 
CTC-led study
Adults with cancer with significant nausea 
or vomiting during cycle 1 of intravenous 
chemotherapy
330 1
BReAST CANCeR (COLLABORATING WITH RACS)
Trials in follow-up
sNAc 1: sentinel node biopsy versus axillary clearance  
RACS and CTC study
women with a single operable breast tumour 
<3 cm, stratified by factors including age and 
tumour size
1000 1088
sNAc 2: sentinel node biopsy versus axillary clearance 
RACS and CTC study
women with operable breast cancer, stratified by 
factors including age and tumour size
 1012 326
GASTROINTeSTINAL CANCeR (COLLABORATING WITH AGITG)
Current trials
ActiccA-1: phase iii trial of adjuvant gemcitabine and cisplatin 
chemotherapy compared with observation
patients with biliary tract cancer after resection 440 (int.) 1 (ANZ);  
160 (int.)
AIO (Germany)-led, AGITG, and CTC study
ALt Gist: imatinib alternating with regorafenib compared to 
imatinib alone for Gist 
Adults with previously untreated metastatic 
gastrointestinal stromal tumours
60 16 (ANZ);  
41 (int.)
AGITG, EORTC , SSG and CTC study
AscoLt: Aspirin for Dukes c and high-risk Dukes b colorectal cancers 
National Cancer Institute (Singapore)-led, AGITG and CTC study
patients with colorectal cancer who have 
completed surgery and other treatment
200 (ANZ); 
1200 (int.)
189 (ANZ); 
976 (int.)
coNtroL Nets: phase ii open-label trial of lutetium-177 octreotate 
added to capecitabine and temozolomide for neuroendocrine 
tumours
patients with pancreatic or midgut neuroendocine 
tumous
72 37
AGITG and CTC study
iNteGrAte ii: phase 3 trial comparing regorafenib and placebo for 
oesophagogastric cancer
patients with refractory advanced oesophageal or 
gastric cancer
90 (ANZ); 260 
(int.)
2 (ANZ);  
0 (int.)
AGITG- and CTC-led international study
interAAct: phase ii open-label trial comparing cisplatin plus 
5-fluorouracil versus carboplatin plus paclitaxel for anal cancer
patients with locally recurrent or metastatic anal 
cancer
80 (int.) 1 (ANZ);  
63 (int.)
Cancer Research UK, AGITG and CTC study
NAbNec: phase ii study of nab-paclitaxel and carboplatin as first-
line treatment 
patients with advanced gastrointestinal 
neuroendocrine carcinoma
70 1
AGITG and CTC
topGeAr: randomised phase ii–iii trial of preoperative 
chemoradiotherapy versus preoperative chemotherapy for gastric 
cancer
patients with resectable gastric cancer suitable for 
these treatments
120 (stage 1); 
632 (stage 2)
120 (stage 1); 
205 (stage 2)
AGITG- and CTC-led international study 
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Trials in follow-up
A La cArt: Australian phase iii randomised trial of laparoscopy-
assisted resection compared with open resection
patients with primary rectal cancer 470 475
AGITG and CTC study
Doctor: phase ii trial of preoperative cisplatin, 5-fluorouracil and 
docetaxel with or without radiotherapy for oesophageal cancer
patients with resectable adenocarcinoma of the 
oesophagus not responsive to chemotherapy
150 registered; 
60 randomised
126 registered; 
66 randomised
AGITG and CTC 
GAp: phase 2 study of gemcitabine and nab-paclitaxel for pancreas 
cancer
patients with resectable pancreas cancer 50 42
AGITG and CTC
icecreAM: irinotecan-cetuximab evaluation and cetuximab 
response evaluation among mutants
patients with Kras wild-type metastatic colorectal 
carcinoma
100 101
AGITG- and CTC-led international study 
petAcc 6: Addition of capecitabine to preoperative oxaliplatin 
chemoradiotherapy and postoperative oxaliplatin chemotherapy for 
rectal cancer (AG0707r)
patients with locally advanced rectal cancer 135 (ANZ); 
1090 (int.)
127 (ANZ); 
1094 (int.)
EORTC (PETACC)-led, AGITG and CTC 
scot: short-course oncology therapy, a study of adjuvant 
chemotherapy in colorectal cancer
patients with fully resected stage iii  
colorectal cancer
225 (ANZ): 
9500 (int.)
213 (ANZ); 
6144 (int.)
MRC-led, AGITG and CTC 
GYNAeCOLOGICAL CANCeR (COLLABORATING WITH ANZGOG)
Current trials
ecHo: exercise during chemotherapy for ovarian cancer  
(ANZGoG 1304)
women with newly diagnosed ovarian cancer 
starting treatment
500 46
ANZGOG and CTC study
outback: phase iii trial of addition of adjuvant chemotherapy to 
standard chemoradiation as primary treatment for cervical cancer 
(ANZGoG 0902)
women with locally advanced cervical cancer 900 (int.) 157 (ANZ);  
701 (int.)
ANZGOG- and CTC-led international study
ovAr2.21: Noninferiority phase iii trial of bevacizumab + 
gemcitabine and carboplatin compared with bevacizumab + 
doxorubicin and carboplatin
women with recurrent cancer sensitive to 
platinum-based treatment
120 (ANZ); 
654 (int.)
76 (ANZ);  
680 (int.)
GCIG-led, ANZGOG and CTC study
pArAGoN: phase ii study of anastrozole in gynaecological cancers 
(ANZGoG 0903) 
ANZGOG- and CTC-led international study
women with potentially hormone-responsive 
gynaecological cancers
 333 (int.) 219 (ANZ); 
114  
(uK, belgium)
reZoLve: phase ii study to evaluate the safety and potential 
palliative benefit of intraperitoneal bevacizumab (ANZGoG 1101)
women with symptomatic ascites due to 
advanced chemotherapy-resistant ovarian cancer
24 19
DGOG-led, ANZGOG and CTC 
Trials in follow-up
GoG182 (icoN 5) 
GOG-led, ANZGOG and CTC
women with advanced stage (fiGo iii-iv) 
epithelial ovarian or primary peritoneal carcinoma.
4200 (int.) 184 (ANZ), 
4312 (int.)
GoG199 
GOG-led, ANZGOG and CTC
women at high risk of ovarian cancer 800 (int.) 83 (ANZ),  
800 (int.)
icoN 6: safety and efficacy of cediranib in combination with 
standard chemotherapy
women with platinum-sensitive relapsed  
ovarian cancer
400 (int.) 17 (ANZ);  
486 (int.)
MRC-led, ANZGOG and CTC 
icoN 7: randomised trial of adding bevacizumab to standard 
chemotherapy
women with epithelial ovarian cancer who have 
not received systemic antitumour therapy
1444 (int.) 76 (ANZ); 
1450 (int.) 
MRC-led, ANZGOG and CTC 
icoN 8: Dose-fractionated chemotherapy compared with 3-weekly 
chemotherapy for ovarian cancer
women with ovarian, fallopian tube or primary 
peritoneal cancer.
145 (ANZ); 
1485 (int.)
70 (ANZ); 
1566 (int.)
MRC-led, ANZGOG and CTC 
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ovAr 16: pazopanib versus placebo for ovarian cancer 
AGO-led, ANZGOG and CTC
women without disease progression after 
chemotherapy for epithelial ovarian, fallopian 
tube, or primary peritoneal cancer
900 (int.) 65 (ANZ);  
940 (int.)
portec 3: chemo radiation and adjuvant chemotherapy compared 
with with pelvic radiation alone in high-risk endometrial carcinoma
women with advanced endometrial carcinoma 120 (ANZ); 
670 (int.)
122 (ANZ); 
688 (int.)
ANZGOG- and CTC-led international study
symptom benefit: Does palliative chemotherapy improve symptoms 
in women with recurrent ovarian cancer? (ANZGoG 0701)
women with platinum-resistant or platinum-
refractory ovarian cancer
200 (ANZ); 
800 (int.)
144 (ANZ); 
948 (int.)
ANZGOG- and CTC-led international study
GeNITOURINARY CANCeR (COLLABORATING WITH ANZUP)
Current trials
bL 12: phase 2 trial comparing nab-paclitaxel with paclitaxel (ANZup 
1401)
patients with metastatic urinary tract cancer and 
previous platinum therapy
100 (ANZ) 35 (ANZ);  
83 (int.)
NCIC-led, ANZUP and CTC study
pain free trus b: phase 3 trial of methoxyflurane with local 
anaesthesia to reduce discomfort of transrectal ultrasound-guided 
prostate biopsy (ANZup 1501)
Men scheduled to undergo first trus biopsy of 
the prostate 
420 (ANZ) 31
ANZUP and CTC study
bcG+MM: phase 3 trial of adding mitomycin to bcG as adjuvant 
intravesical therapy (ANZ 1301)
patients with high-risk, non-muscle-invasive 
bladder cancer
500 92
ANZUP and CTC study
eNZAMet: phase 3 trial of enzalutamide in androgen-deprivation 
therapy for prostate cancer (ANZup 1304)
Men with metastatic prostate cancer 1100 615 (ANZ): 
373 (int.)
ANZUP and CTC study
eNZArAD: phase 3 trial of enzalutamide in androgen-deprivation 
therapy for localised prostate cancer (ANZup 1303)
Men with high-risk localised prostate cancer 800 306 (ANZ);  
73 (int.)
ANZUP and CTC study
p3bep: phase 3 trial of accelerated versus standard bep 
chemotherapy (ANZup 1302) 
ANZUP and CTC study
patients with intermediate and poor-risk 
metastatic germ-cell tumours
stage 1:  
90 (ANZ)
stage 2: 350
32 (ANZ)
Trials in follow-up
chemo & cognition: cognitive function and treatment for testicular 
cancer (ANZGctG 0106)
patients being treated and followed up for 
testicular cancer
154 151
ANZUP and CTC 
eversuN: phase ii trial of everolimus alternating with sunitinib for 
renal cell carcinoma (ANZup 0901)
patients starting first-line systemic therapy for 
advanced renal cell carcinoma
55 56
ANZUP and CTC 
sorce: Adjuvant sorafenib for renal cell carcinoma (re 05) 
MRC-led, ANZUP and CTC
patients with resected renal cell carcinoma at 
intermediate or high risk of relapse
 250 (ANZ); 
1656 (int.)
168 (ANZ); 
1711 (int.)
LUNG CANCeR (COLLABORATING WITH ALTG)
Trial in start-up
NivorAD: nivoumab and stereotactic radiotherapy versus 
nivolumab alone
patients with advanced non-smal- cell lung cancer 
progressing after chemotherapy
120
ALTG and CTC
peArL: phase 3 trial of palliative care early in advanced lung cancers 
ALTG and CTC
Adults with advanced lung cancer newly 
diagnosed within the last 60 days
200
Current trial
br.31: phase iii study of adjuvant MeDi4736  
NCIC-led, ALTG and CTC
patients with resected primary stage ib (>4 cm), ii 
or iiiA non-small-cell lung cancer
200 (ANZ);
1100 (int.)
18 (ANZ);  
280 (int.)
DreAM: phase 2 study of durvalumab with first-line chemotherapy 
ALTG and CTC 
patients with malignant pleural mesothelioma 
not amenable to surgery
51 1
42 
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BRAIN CANCeR (COLLABORATING WITH COGNO)
Current trials
AceD: phase ii study of acetazolamide + dexamethasone v 
dexamethasone alone for cerebral oedema 
COGNO and CTC
Adults with recurrent or progressive high-grade 
glioma, who require dexamethasone or dose 
increase for cerebral oedema
84 1
vertu: veliparib, radiotherapy and temozolomide in glioblastoma 
COGNO and CTC
patients with newly diagnosed resected 
glioblastoma with unmethylated MGMt 
promoter gene
120 124 registered; 
40 randomised
Trials in follow-up
cAtNoN: phase iii trial of concurrent and adjuvant temozolomide 
chemotherapy for anaplastic glioma (eortc 26053-22054)
patients with non-1p/19q-deleted anaplastic 
glioma
100 (ANZ); 
748 (int.)
82 (ANZ); 751 
(int.)
EORTC-led, COGNO and CTC 
funDIng
ctc has continued to receive 
highly sought-after peer reviewed 
funding from Australia, united 
Kingdom and the united states. 
the Nsw government and 
national funding bodies also 
continue to provide crucial 
support. 
pharmaceutical industry support 
reflects the strength of ctc’s 
collaborative relationships, 
research quality and innovative 
edge in academic clinical trials. 
total income for 2016: 
$34,496,180
42 
industry 21%
peer-
reviewed 
grants 40%
other public 
grants 20%
interest and donations 1%
university 
grants 7%
consulting 4%
education and training 4%
other 3%
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rebecca Asher, bsc, Msc
Luke buizen, bsc
Lucy Davies, bsc, Msc
Mark w Donoghoe, bsc(Adv)(hons), phD
David espinoza, bArch(hons), bsc(hons)
emma Gibbs, bsc, Msc
Kristy p robledo (Mann), bscAgr (hons), 
Mbiostat
simone Marschner, bsc(hons), Msc
Biostatistics Collaboration of Australia 
(BCA)
erica Jobling, executive officer
emily Higginson, bA/bsc, senior 
administration officer
Information systems
Infrastructure
Dinh tran, bMath, Mcompsc, infrastructure 
manager
Ha Le, bit, computer systems officer
Asanka perera, bsc, computer systems officer
ryan sausa, be, computer systems officer
thuyen vu, bsc, computer systems officer
Database administration
Anh tai Nguyen, bMath, database 
administrator
Software development
colin sutton, bsc, Msc, it systems 
development manager
seshu Atluri, be, software engineer
business administration
vera terry, bsc, phD, LLb, GradDipLp, Mip, 
MbA, general manager
Libby cregan, administration assistant
Lena Germinarios, administration assistant 
(from July)
rodd Hills, administration assistant (to July)
Lia sherwood, bbiomedsc, Msc, grants and 
contracts coordinator
Finance
paul smyth, bcom, cpA, finance manager
Agnes Ho, MpracAcc, cpA, finance officer
Maki Joseph, Diped, finance officer
carlos sterling, beng, MbA, finance officer
Human resources
cynthia carr, bed(HrD), human resources and 
administration manager
suzanne everett, bsw, human resources and 
administration coordinator
publications
rhana pike, bA, MA, Gradcert, eLs, cMpp, 
Mwc
research students
Daniel Calandro, BSc
Ryan Farr, BSc, MPhil
Jordan fulcher, bsc(Med), Mb bs, frAcp
Deme Karikios, bsc, Mb bs, frAcp
Nicola Lawrence, bHb, Mb chb, frAcp
Anna Martin 
emma scott, Mb bs
Hang yue Adrian sui
boris waldman, bsc, Mb bs
wilson wong, bsc(hons)
academic staff
Hany Abed, bpharm, Mbbs, phD, research 
fellow
Lisa M Askie, bN, MpH, phD, associate 
professor and principal research fellow
elizabeth H barnes, bAppsc, Mstat, research 
fellow
christopher sb brown, bsc, Mbiostat, 
research fellow
In March, Karen Bracken received 
a Faculty of Medicine award for 
exceptional performance
Lia Sherwood, grants coordinator
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Karen byth, bsc(hons), Msc, phD, Dic, cstat 
rss, senior lecturer
val J Gebski, bA, Mstat, professor and 
principal research fellow
wendy Hague, Mb bs, MbA, phD, senior 
research fellow
Anandwardhan A Hardikar, bsc, Msc, phD, 
associate professor and Juvenile Diabetes 
research foundation Australia type 1 
diabetes clinical research network fellow
philip J Hogg, bsc, phD, senior principal 
research fellow and professor
Mugdha Joglekar, bsc, Msc, phD, research 
fellow
Andrzej s Januszewski, MD, phD, senior 
research fellow
Alicia J Jenkins, Mb bs, MD, Mrcp, frAcp, 
frcp, professor
Anthony c Keech, Mb bs, Msc, frAcp, 
fcsANZ, fAHMs, principal research fellow 
and professor
Adrienne c Kirby, bsc(hons), Msc, senior 
lecturer
Mustafa Khasraw, Mbchb, MD, Mrcp, frAcp, 
senior research fellow
Henry Ko, beng(Med)(hons), phD, research 
fellow
peey sei Kok, Mb chb, research fellow
Nicola Lawrence, bHb, Mb chb, frAcp, 
research fellow
chee K Lee, Mb bs(hons), MMedsc, Mbiostat, 
phD, frAcp, senior research fellow
Kristina Lindemann, MD, phD, clinical research 
fellow, ANZGoG trials
sally (sarah) J Lord, Mb bs, Dippaed, Msc, 
frAcGp, senior research fellow
ian c Marschner, bsc(hons), phD, professor
Andrew J Martin, bA, MA, GradDip, phD, 
Astat, senior lecturer
rachael Morton, MscMed (clinepi)(hons), 
phD, associate professor
rachel L o’connell, bMath, MMedstat, phD, 
senior research fellow
felicia roncolato, Mbchb, clinical research 
fellow, ANZGoG and ANZup trials
r John simes, bsc(Med)(hons), Mb bs(hons), 
MD, sM, frAcp, fAHMs, senior principal 
research fellow and professor
Katrin M sjoquist, bsc(Med), Mb bs, 
Mclintres, frAcp, senior research fellow
Martin r stockler, Mb bs(hons), Msc, frAcp, 
professor
william o tarnow-Mordi, Mrcp(uK), 
frcpcH, professor
subotheni thavaneswaran, Mb bs, research 
fellow
Annette tognela, LLb/bsc, Mb bs, research 
fellow
sonia yip, bsc(hons), phD, senior research 
fellow
CTC research associates
Associate professor Meera r Agar 
Dr yoland Antill
professor Andrew barbour
Dr Andrew berry
professor Andrew biankin
Associate professor Alex boussioutas
Associate professor Alison brand
Dr tim brighton
Associate professor ian campbell
Dr yu Jo chua
professor Alan coates
Ms Melinda cruz
Dr Andrew Davidson
professor ian Davis
professor paul de souza 
Dr Andrew Dean 
professor catherine D’este
Dr John eikelboom
Dr Kathryn field
Ms Marcia fleet
Dr Matthew foote
Dr Michael friedlander
Adjunct professor Davina Ghersi
professor p Grantley Gill
professor David Goldstein
Associate professor peter Grimison 
Dr Andrew Haydon
Associate professor sandra Hayes
professor Dickon Hayne
professor Gillian Heller
Dr elizabeth Hovey 
Associate professor Michael Jefford 
Dr Lindy Jeffree
Associate professor terrance Johns
Associate professor Anthony Joshua
Dr eng-siew Koh
Dr Dusan Kotasek
Dr Danette Langbecker
Ms robyn Leonard
Dr trevor Leong
Associate professor Helen Liley
professor ronald Ma
Dr Kerrie McDonald
Dr sue-Anne McLachlan
Associate professor peter Meikle
Associate professor Linda Mileshkin
professor Michael J Millward
Associate professor paul Mitchell
Associate professor Martin Ng
Dr Louise Nott
professor Anna Nowak
Associate professor paul Nguyen
Dr Graham ogle
Associate professor Ju-Lee oei
Associate professor David o’Neal
Dr robert padbury
Dr Nicholas J petrelli
professor timothy J price
Dr David t ransom
professor Danny rischin
professor Mark rosenthal
Dr Amitesh roy
Dr Gail ryan
Associate professor eva segelov
Associate professor shomik sengupta
Dr catherine shannon
Dr Jennifer A shannon
professor Karen simmer
professor Mark smithers
Dr Allan spigelman
Dr Andrew r stevenson
Associate professor tobias strunk
Associate professor David sullivan 
professor christopher sweeney
Associate professor Niall tebbutt
professor David thomas
Associate professor Damien thomson
professor Andrew tonkin
Dr ben tran
Associate professor euan walpole
Dr Neil wetzig
Associate professor Nicholas wilcken
Associate professor scott williams
professor Gary wittert
professor Desmond yip
professor John Zalcberg
 NHMrc cLiNicAL triALs ceNtre: 2016 reseArcH report 47
STaff aCTIvITIeS
STaff aCTIvITIeS
Supervision of postgraduate 
research in 2016
John Simes
Jordan fulcher, Doah cho, Nicola Lawrence, 
Katrin sjoquist
Anthony Keech
Karen bracken, Daniel calandro, Jordan 
fulcher, surya sutanto, caroline traill, boris 
waldman, ceren Guler, Grace McKenzie, 
Georgia shimmin, Amanda ifejika, patrick 
rundle
Lisa Askie
Ziad Al-rubiae
Val Gebski
Alan Garner
Wendy Hague
Karen bracken
Anandwardhan Hardikar
erin bell, Luke carroll, ryan farr, emma scott, 
ella somerville Glover, Malati umrani, 
wilson wong
Andrzej Januszewski
Daniel calandro, ben Ma, Aycel Al-Alosi
Alicia Jenkins
emma scott, erin bell, yoon Hi cho, ben Ma, 
Harris schlen, Daniel calandro, caroline 
traill, ryan farr,christine Larsson, Joanne 
Lee, Gabriel Gregory, Denira Govendir, 
yifan Zang, william yuen, feng chunzhi 
cao, eugene Hao Jun Ng, Jessica Ng, Laura 
Nichols, benjamin Zhu
Mugdha Joglekar
emma somerville Glover, wilson wong
Chee Lee
Amira elmadahm, felicia roncolato, Doah 
cho
Sally Lord
Amira elmadahm, Doah cho
Andrew Martin
Deme Karikios, Nicola Lawrence, erin Moth, 
rashi Minocha
Rachael Morton
caroline watts, Mbathio Dieng, rachael 
walker, Melanie wyld, Marcus sellars, 
Laverne Lok, Anna Martin
Martin Stockler
Deme Karikios, Nicola Lawrence, rebecca 
Mercieca-bebber, felicia roncolato, Katrin 
sjoquist, puma sundaresan, Anuradha 
vasista
Degrees awarded in 2016
Mark Donoghoe, phD
Manjula schou, phD
external committees
John Simes
Advancing the evidence base program grant 
research committee
Aspire and iNspire steering committees 
(chair)
Australasian Gastro-intestinal trials Group 
(AGitG) scientific advisory committee, 
operations executive committee
Australia and New Zealand breast cancer 
trials Group (ANZbctG) scientific advisory 
committee
Australian clinical trials Alliance (ActA) 
founding member and chair, governance 
working group
Australian New Zealand clinical trials registry 
(ANZctr) policy advisory committee
boost ii, Apts and Lift trial management 
committees (neonatal)
cholesterol treatment trialists collaboration 
(cttc) (joint coordinator)
cochrane breast cancer Group editor
cooperative trials Group for Neuro-oncology 
(coGNo) scientific advisory committee, 
management committee (deputy chair), 
operations executive
eNcHANteD safety and data monitoring 
committee (chair)
fieLD management committee and executive
LipiD management committee and executive
Molecular screening and therapeutics 
program (Most) steering committee
sNAc trial management committee
sydney catalyst governing council and 
scientific advisory committee (director)
vertu and AceD trial management 
committees (coGNo)
Anthony Keech
Advancing the evidence base program grant 
research committee
Australian Academy of Health and Medical 
sciences fellowship review committee
Australian clinical trials Alliance (ActA) 
founding member
cholesterol treatment trialists’ collaboration 
(cttc) (joint coordinator and convener)
clinical trials centre research committee 
(chair)
Department of Health post Market review 
committee
fAMe-1 diabetes trial steering committee 
(co-chair)
fieLD management committee (principal 
investigator and study chairman), and 
quality-of-life and cost-effectiveness, 
ophthalmology, and scientific substudies 
committees
further cardiovascular outcomes research 
with pcsK9 inhibition in subjects with 
elevated risk (fourier) executive 
committee
International Journal of Cardiology editorial 
board
LipiD study management committee and 
executive
New south wales Department of Health 
shared assessment committee
PLoS Medicine editorial board
rebecca cooper grant review committee
reMovAL trial steering committee
royal prince Alfred Hospital clinical trials 
(ethics) subcommittee
university of sydney Department of public 
Health research committee
Lisa Askie
AMicAbLe, MAppiNo, pAris, precise, and 
previLiG collaboration steering committees
Australian New Zealand clinical trials registry 
operational executive committee
clinical trials centre research committee and 
neonatal executive committee
clinical trials sub-committee, royal prince 
Alfred Hospital Human research ethics 
committee
cochrane collaboration prospective meta-
analysis methods group (convener), 
neonatal collaborative review group, 
handbook advisory group and individual 
participant data methodology group
ccpt collaboration, co-chairperson
epocH and NeoproM collaborations, chair
German clinical trials registry and pan African 
clinical trials registry scientific advisory 
committees
international forum for standards for 
research in children sample size and data 
safety monitoring subcommittee
ippic steering committee
NHMrc assigners academy, Australian 
clinical trials website portal advisory group, 
national ethics application form advisory 
group, National trials core competencies 
advisory group, National statement 
chapter 3 revision working Group, research 
translation faculty.
proMpt, prisMA-c, and stArD trial 
registration advisory Groups
Systematic Reviews editorial board
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elizabeth Barnes
biostatistics collaboration of Australia 
teaching committee
cooperative trials Group for Neuro-oncology 
(coGNo) scientific advisory committee 
and vertu and AceD trial management 
committees
Doctor trial management committee 
(AGitG)
outback and ecHo trial management 
committees (ANZGoG)
Karen Bracken
t4DM study steering committee
Chris Brown
Australasian Lung cancer trials Group (ALtG) 
operations executive and scientific advisory 
committees
basic sciences in oncology, Health education 
and training institute
Sarah Chinchen
Australasian Lung cancer trials Group (ALtG) 
operations executive committee br.31 trial 
management committee
Jenny Chow
cancer institute Nsw Neuro-oncology Group 
(NswoG)
cooperative trials Group for Neuro-oncology 
(coGNo) operations executive, annual 
scientific meeting organising committee
clinical oncology society of Australia (cosA) 
executive officers network, and associated 
working groups 
brain cancer biobanking Australia (bcbA) 
operations group
Xanthi Coskinas
eNZArAD executive, international steering 
and trial management committees
eNZAMet executive, international steering 
and trial management committees
Val Gebski
Advancing the evidence base program grant 
research committee
cHivA, coMpAss, ewoc-1; ovAr2.21, 
prevANZ and preveNt safety and data 
monitoring committees
Australasian Gastro-intestinal trials Group 
(AGitG) scientific advisory committee and 
group statistician, and A La cart, ALt-Gist, 
topGeAr, Doctor and icecreAM trial 
management committees
Australasian Kidney trials Network advisory 
board
Australia and New Zealand breast cancer 
trials Group (ANZ bctG) scientific 
advisory committee and group statistician, 
and eLiMiNAte and prospect trial 
management committees
Australian and New Zealand urogenital 
and prostate cancer trials Group ANZup 
scientific advisory committee and group 
statistician, and Accelerated bep trial 
management committee
Australian New Zealand Gynaecological 
oncology Group (ANZGoG) research 
advisory committee and group statistician, 
and soLo2 trial management committee, 
pArAGoN and outbAcK trial management 
committees
biostatistics collaboration of Australia 
steering committee
coMpAss (cervical screening) and reiNvest 
(reducing impulsivity in repeat violent 
offenders) trial steering committees
crown princess Mary cancer care centre 
(westmead) radiation oncology research 
committee
Laparoscopic surgery versus Hysterectomy in 
patients with cervical cancer (LAcc) trial 
management committee
Nsw Health central sydney Area ethics 
committee clinical trials subcommittee
sNAc and t4DM trial management 
committees
trans tasman radiation oncology Group 
(troG) scientific committee, publications 
committee, and group statistician
Alpana Ghadge
boost ii, Lift, LeAp, torpido2, pAeAN and 
protect trial management committees
sydney international update management 
committee
Wendy Hague
Aspire, and LipiD management committees 
(cardiovascular)
Australasian Gastro-intestinal trials Group 
(AGitG) trials operations committee and A 
La cart trial management committee
Apts, boost ii, LeAp, pAeAN and protect 
management committees (neonatal)
Molecular screening and therapeutics 
program (Most) steering committee
t4DM trial management committee
Merryn Hall
cooperative trials Group for Neuro-oncology 
(coGNo) operations executive committee
vertu, AceD and cAtNoN trial management 
committees (coGNo)
Anandwardhan Hardikar
1000 qataromics study, co-principal 
investigator and Australian lead investigator
Australian research council and Juvenile 
Diabetes research foundation Australia 
rApiD study and preDict type 1 diabetes 
clinical research network principal 
investigator
center of excellence in epigenetics, indian 
institute for science education and research 
visiting professor
Danish Diabetes Academy, visiting professor
islet society vice-president
Lifestyle interactions in fenofibrate and 
the epigenome (fieLD-Life) study (co-
investigator)
Nature Scientific Reports and Islets editorial 
boards
NHMrc grant review panel for diabetes, 
obesity, stem cell panels, project grant 
review committee, translational research 
faculty member and assigners academy 
member
Non-coding RNAs in Endocrinology, editor-in-
chief
Philip Hogg
fAseb science research conference on 
functional Disulfide bonds in Health and 
Disease, convener and chair
Andrzej Januszewski
e-preDice trial steering committee
fAMe-1 diabetes trial steering committee 
Alicia Jenkins
Australian Diabetes society committees: 
disaster response; lipid guidelines, and type 
1 diabetes consulting skills book
Diabetes control and complications trial and 
epidemiology of Diabetes interventions and 
complications study cardiovascular disease 
biomarker writing committees
Diabetes Management Journal and Diabetes 
Reviews editorial boards
fAMe-1 diabetes trial steering committee 
(co-chair)
insulin for Life Australia, insulin for Life global 
president and insulin for Life usA board 
member
international Diabetes federation Life for a 
child program board member
international Diabetes federation western 
pacific executive council
Juvenile Diabetes research foundation clinical 
research network advisory board, and lead, 
research node at ctc
reMovAL metformin study, co-principal 
investigator and Australian lead
t4DM trial steering committee
teAMsNet telehealth initiative principal 
investigator
Mustafa Khasraw
Asian society of Neuro-oncology meeting 
scientific chair
Australian Medicare benefit scheme oncology 
clinical committee
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cancer Australia breast cancer best practice 
advisory group
NAbNec trial lead (AGitG)
NeoNAb trial lead and Local Her-o trial 
committee (breast cancer)
NHMrc grant review panel
NutMeG, vertu, and excentric trial lead, 
GbM AGiLe executive committee and AceD 
trial committee (brain cancer)
tuLip trial lead (lung cancer)
Hannora Jurkovic
Australasian Lung cancer trials Group (ALtG) 
operations executive committee, br.31 trial 
management committee
Adrienne Kirby
Apts, boost ii and torpiDo2 trial 
management committees (neonatal)
faculty of Medicine, university of sydney 
postgraduate coursework committee
improving Delivery of secondary prophylaxis 
for rheumatic Heart Disease trial 
management committee
iNspire steering committee
LipiD management committee
Master of clinical trials (research) coursework 
teaching committee
randomised trial on surgical treatment for 
otitis Media in children Living in remote 
Australian communities trial management 
committee
royal prince Alfred Hospital clinical trials 
(ethics) subcommittee
Chee Lee
Australasian Lung cancer trials Group small-
cell lung cancer co-chair
ANZ breast cancer trials Group scientific 
advisory committee
Genomic cancer clinical trials initiative 
(Gccti)
Molecular screening and therapeutics 
program (Most) steering committee
study of olaparib clinical effect (soLAce) trial 
management committee
Liping Li
e-preDice trial steering committee
fAMe-1 diabetes trial steering committee 
Ann Livingstone
Australasian Lung cancer trials Group (ALtG) 
operations executive and scientific advisory 
committees
Sally Lord
european federation of clinical chemistry 
and Laboratory Medicine test evaluation 
working group
patient-centered research for standards of 
outcomes in diagnostic tests group
protocol advisory subcommittee (pAsc) for 
Medical services Advisory committee
Ian Marschner
Advancing the evidence base program grant 
research committee
Australasian Gastro-intestinal trials Group 
(AGitG) independent data and safety 
monitoring committee
Apts trial independent data and safety 
monitoring committee
biostatistics collaboration of Australia 
steering committee
Andrew Martin
Australia & Asia pacific clinical oncology 
research Development (AcorD) workshop 
statistical working group
Australian and New Zealand urogenital and 
prostate cancer trials Group (ANZup) 
scientific advisory committee
iNteGrAte ii, p3bep, bcG+MM, Lift, 
oNtrANs, epocH, score, cHest and 
LeAD trial management committees
royal prince Alfred Hospital clinical trials 
subcommittee of the ethics review 
committee
Danielle Miller
Australasian Gastro-intestinal trials Group 
(AGitG) topGeAr trial management 
committee.
sydney catalyst operations group, executive, 
scientific advisory committees, and themed 
working groups. 
primary care collaborative cancer clinical 
trials Group (pc4) advisory group.
Rebecca Mister
iNspire management committee
sNAc1 and sNAc2 trial management 
committees
Meeting of the advisory committee of the Australian New Zealand Clinical Trials Registry
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Rachael Morton
Australia and New Zealand society of 
Nephrology, Dialysis Advisory committee
cochrane economics methods and equity 
methods groups
Joanna briggs institute expert reference group
Health economics collaboration (Hec), 
steering group
Health services research Association 
Australian and New Zealand, treasurer
Melanoma genomics for prevention, trial 
management committee
Australian and New Zealand dialysis and 
transplant Association) registry patient 
reported outcomes working group member
Nephrology, Dialysis, transplantation editorial 
board
whole brain radiotherapy for metastatic 
melanoma, evaluation of Groin 
Lymphadenectomy extent for Metastatic 
Melanoma, and Mel-D trial management 
committees (Australia and New Zealand 
Melanoma trials Group)
cArsK trial management committee 
(Australian Kidney trials Network)
effectiveness of social dancing as a strategy to 
prevent falls in older people (DANce) trial 
committee
Rachel O’Connell
D-Health trial management committee
pArAGoN and symptom benefit trial 
management committees (ANZGoG)
tActic and topGeAr trial management 
committees (AGitG)
LeAp1 and pAeAN trial management 
committees (neonatal)
Kristy Robledo
t4DM trial management committee
Apts management committee
Kate Sawkins
Australasian Lung cancer trials Group (ALtG) 
operations executive and scientific advisory 
committees
Australia New Zealand Gynaecological 
oncology Group (ANZGoG) operations 
executive
cooperative trials Group for Neuro-oncology 
(coGNo) operations executive and scientific 
advisory committees
Lucille Sebastian
Apts and Apts echo substudy trial 
management committees
interdisciplinary Maternal perinatal 
Australasian collaborative trials (iMpAct) 
network steering committee
Molecular screening and therapeutics 
program (Most) operations and steering 
committee and molecular tumour board
Most substudy management committees: 
palbociclib, durvalumab plus tremelimumab, 
olaparib plus durvalumab
pharmacodynamic effects of the heat shock 
protein 90 (Hsp90) inhibitor Auy922 in 
high-risk, localised prostate cancer (Hsp 
90 inhibitor study) trial management 
committee
Katrin Sjoquist
Australia Asia-pacific clinical oncology 
research Development (AcorD) workshop 
steering committee, alumni committee 
(chair), faculty member
Australia New Zealand Gynaecological 
oncology Group (ANZGoG) research 
advisory committee and operations 
executive committee
symptom benefit, pArAGoN, ovAr2.21 trial 
management committees, reZoLve trial 
management committee and study co-chair
Australasian Gastro-intestinal trials Group 
(AGitG) scientific advisory committee and 
operations executive committee, upper & 
Lower Gi working parties
coNtroL-Nets, iMpAct, tActic, ActiccA 
trial management committees
iNteGrAte 1 & 2 trial management 
committees (ctc clinical lead) and 
international trial management group,
Genomic cancer clinical trials initiative 
(Gccti)
NHMrc grant review panel
Molecular screening and therapeutics 
program (Most) clinical lead, substudy 
module chair, steering committee
Martin Stockler
Advancing the evidence base program grant 
research committee
Australasian Lung cancer trials Group 
(ALtG) scientific advisory committee 
and operations executive, br31, DreAM, 
NivorAD, and peArL trial management 
committees
Australia Asia-pacific clinical oncology 
research Development (AcorD) workshop 
steering committee (convener and chair)
Australia New Zealand Gynaecological 
oncology Group (ANZGoG) research 
advisory committee, ecHo, outbAcK, 
pHAeDrA trial management committees
Australian and New Zealand urogenital and 
prostate cancer trials Group (ANZup) 
scientific advisory committee (deputy 
chair), operations executive and chemo & 
cognition, and eversuN and sorce trial 
management committees
cancer council Australia national oncology 
education committee
National Health and Medical research council 
grant review panels for oncology
university of sydney faculty of Medicine 
oncology block committee (chair), ebM 
in GMp3/4 (chair), evidence-based 
medicine resource group, integrated clinical 
attachment committee and university of 
sydney Medical program cancer planning 
committee
William Tarnow-Mordi
Apts, boost ii, LeAp 1, Lift, and torpido2 
trial management committees
iMpAct trial management committee
NHMrc grant review panel for clinical trials
sydney international update on Advances in 
perinatal care organizing committee chair
eric Tsobanis
coNtroL Nets trial management 
committee
iNteGrAte executive and trial management 
committees and international trial 
management group
iNteGrAte ii executive and trial management 
committees and international trial 
management group
Burcu Vachan
Australia New Zealand Gynaecological
oncology Group (ANZGoG) and Australian 
and New Zealand urogenital and prostate 
cancer trials Group (ANZup) operations 
executive committees
Melina Willson
cochrane managing editors’ executive
Guidelines international Network (GiN) 
implementation working group
Kate Wilson
Australasian Gastro-intestinal trials Group 
(AGitG) operations executive committee, 
scientific advisory committee and annual 
scientific meeting committee, and A 
La cart, AttAcHe, coNtroL-Nets, 
petAcc6, and quAsAr2 trial management 
committees.
Nicole Wong
Australian and New Zealand urogenital and 
prostate cancer trials Group (ANZup) 
operations and scientific advisory 
committees, and bL.12, trus b, bcG+MMc, 
eversuN, sorce, p3bep, chemo & 
cognition, tiGer and Accelerated bep trial 
management committees
cannabisciNv trial executive and 
management committees
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Sonia Yip
Australasian Gastro-intestinal trials Group 
(AGitG) operations executive, scientific 
advisory committee and biological 
subcommittee, AGitG-Ncic-ctG correlative 
research committee, and ActiccA, ALt-
Gist, AscoLt, GAp, iMpAct, iNteGrAte 
i, iNteGrAte ii and NAbNec trial 
management committees
Australasian Lung cancer trials Group (ALtG) 
scientific advisory committee
Australia New Zealand Gynaecological 
oncology Group (ANZGoG) research 
advisory committee, cervix working group, 
endometrial working group and reZoLve 
trial management committee.
Australian and New Zealand urogenital and 
prostate Group (ANZup) scientific advisory 
committee, renal cell subcommittee, 
germ cell subcommittee, translational 
research subcommittee, and eversuN, 
sorce, eNZAMet, eNZArAD, p3bep trial 
management committees, eNZAMet 
and eNZArAD international translational 
research steering committee
cooperative trials Group for Neuro-oncology 
(coGNo) vertu trial management 
committee
sydney catalyst scientific advisory committee, 
operations executive committee, t1/t2 
working group; Lc-pLAt management 
committee, post-Graduate and early career 
researcher symposium 2015 convener
cancer institute Nsw biobanking stakeholder 
Network working Group
Genomic cancer clinical trials initiative 
(Gccti) project team
regular academic teaching
Anthony Keech
royal prince Alfred Hospital cardiology 
training, and clinical tutor
controlled clinical trials, Master of public 
Health and Master of Medicine, university 
of sydney
Master of clinical trials, university of sydney 
(co-coordinator)
Lisa Askie
Advanced systematic reviews, Master of 
clinical epidemiology, university of sydney 
(co-coordinator)
controlled clinical trials, Master of public 
Health and Master of clinical epidemiology, 
university of sydney
critical appraisal of evidence, Master of clinical 
trials, university of sydney
elizabeth Barnes
Australia & Asia pacific clinical oncology 
research Development (AcorD) faculty
basic sciences in oncology, Health education 
and training institute
principles of statistical inference, biostatistics 
collaboration of Australia (coordinator)
statistical principles and clinical trials, Master 
of clinical trials research, university of 
sydney (coordinator)
Chris Brown 
Australia & Asia pacific clinical oncology 
research Development (AcorD) faculty 
basic sciences in oncology, Health education 
and training institute
controlled clinical trials, Master of public 
Health and Master of Medicine, university of 
sydneycapstone project, Master of clinical 
trials, university of sydney (coordinator) 
Mark Donoghoe
basic sciences in oncology, Health education 
and training institute
David espinoza
critical appraisal of evidence, Master of clinical 
trials research, university of sydney
Val Gebski
basic sciences in oncology, Nsw cancer 
council
controlled clinical trials, Master of public 
Health and Master of Medicine, university 
of sydney
royal Australian and New Zealand college 
of radiologists radiation oncology training 
(sMArt)
emma Gibbs
Master of clinical trials research, university 
of sydney
basic sciences in oncology, Health education 
and training institute
Deme Karikios
Decision analysis, Master of public Health and 
Master of Medicine, university of sydney
evidence-based medicine in the clinical years, 
and oncology and palliative care, university 
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